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 II   
ABSTRACT 
 
INTRODUCTION 
In 2013, NICE published new guidance (CG168) for the management of lower limb 
venous disease; these guidelines sought to improve access to secondary care and 
recognised newer endovenous treatment modalities sufficiently robust to recommend. No 
formal study had evaluated the effect of the introduction of Guideline CG168 on venous 
disease management; this prompted the research project embodying this thesis.  
 
METHODS 
The management of venous disease was investigated locally at a secondary care level with 
primary care management being studied via the Health Improvement Network Database 
 
RESULTS 
Local secondary care has improved significantly since the introduction of CG168, 
demonstrating an increased use of endovenous treatments at earlier stage of venous disease. 
A significantly higher number of patients are being referred for specialist review with leg 
ulceration. 
An improvement in referral and management of varicose veins in the community setting 
was noted, however the increase in referral for leg ulceration was more modest, with 
 III   
patients often not referred at all for secondary care assessment. 
 
CONCLUSION 
Whilst current data presented here suggests enhanced management of superficial venous 
disease, nationwide primary care improvements have been less marked. Further efforts will 
be required to continue to publicise the importance of NICE Guideline CG168 in order to 
extend its beneficial effects on patient care. 
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Chapter 1 
INTRODUCTION 
 
1.1  THE PROBLEM OF CHRONIC VENOUS DISEASE: 
1.1.1    Pathophysiology of Venous Disease 
Varicose veins are defined as dilated, tortuous veins of the superficial venous system. They 
are most commonly found in the lower limb. These veins exhibit reversed venous blood 
flow (reflux), which results in venous hypertension of the lower limb.  
 
The venous system of the lower limb is divided into two components, the deep and 
superficial systems, separated by a fascial layer. Deep veins situated in the calf muscles 
converge to form the popliteal vein, this in turn becomes the femoral, common femoral and 
finally the external iliac vein before the right and left common iliac veins combine to form 
the inferior vena cava. The superficial system comprises of the small and great saphenous 
veins, both veins are connected through the fascia of the leg to the deep system at the 
sapheno-popliteal and sapheno-femoral junctions respectively. There are further 
anastomoses from superficial to deep systems from perforating veins along the length of 
the lower limb. In the normal physiological state, blood flows proximally along the deep 
system and from superficial to deep systems as a result of contraction of the calf muscle 
pump. Reverse flow from proximal to distal and from deep to superficial systems is 
prevented by a system of valves. 
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Chronic venous insufficiency occurs as a result of disturbance to normal flow. This may be 
primary or secondary (e.g. venous incompetence from deep vein thrombosis). Three 
factors are responsible for the development of chronic venous insufficiency: failure of the 
calf muscle pump (inactivity), failure of valves and obstruction to venous flow (e.g. deep 
vein thrombosis). Any combination of these results in venous hypertension, forcing fluid 
and protein out of the vein resulting in the skin changes associated with chronic venous 
insufficiency. In spite of the general acceptance of the previously mentioned features, the 
exact aetiology of the pathogenesis of varicose veins remains uncertain. A systematic 
review by Lim 1 suggests several methods for venous insufficiency – however, once 
venous reflux is detectable clinically and with duplex ultrasonography, all of these 
processes have begun and therefore it is difficult to elucidate the initiating cause or causes 
(Figure 1.1.1). 
Figure 1.1.1    Pathogenesis of Venous Insufficiency, Adapted From Lim et al1 
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The most common presentations of chronic venous disease are reticular veins, 
telangiectasia and varicose veins. This progresses to chronic venous insufficiency resulting 
in venous hypertension of the lower limbs. The consequences of chronic venous 
insufficiencies are patient symptoms, e.g., pain, leg swelling, skin changes (venous eczema, 
haemosiderin deposition and lipodermatosclerosis) and venous leg ulceration. 
 
1.1.2    Epidemiology of Venous Disease 
 
In 1999 the Edinburgh Vein Study found an age-adjusted prevalence of venous disease 
(trunk varices) of 40% and 32% in men and women respectively 2. The United States has 
approximately 25 million inhabitants suffering from simple varicose veins and around 6 
million suffering from more advanced venous disorders 3 (superimposed skin changes and 
ulceration). The increasing awareness of the high incidence and prevalence of venous 
disease and its associated morbidity, led the American Venous Forum to conduct the 
National Venous Screening Programme, publishing the results of the second survey in 
2008. This identified varicose veins in >30% of it’s 2234 participants and more advanced 
venous disease in >10% 4.  In 2010 rates of 25% were found by the BONN vein study II 5. 
Follow up to the Edinburgh Vein study found over a 13 year period, an incidence of 
around 1% of the population developing venous reflux per year 6; this was comparable to 
the annual incidence described in the Framingham study in 1988 (1.9% for males and 2.6% 
for females) 7. Prevalence, appears to vary with the geographical location of studied 
patients and appears higher in more developed countries. Mekky et al 8 found the 
prevalence of varicose veins in England was five times that in Egypt although they 
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concluded that environmental factors probably played a more important role than 
ethnic/genetic differences. 
 
Geographical and/or environmental influences were also suggested by a study of different 
populations in the South-Pacific; higher rates of varicose veins were seen in New Zealand 
compared with atoll-dwelling islanders 9, 10. In Jerusalem, the country of birth appeared to 
affect the prevalence, it was found to be reduced in people from North Africa when 
compared to those born in America, Asia and Europe 11. In Europe it has been noted that 
the prevalence was lower in Southern European women (e.g. Italy and Spain) compared to 
other European countries (e.g. Switzerland, France and countries of central Europe) 12.  
The San Diego Population Study demonstrated a higher prevalence of visible varicose 
veins in Hispanics (26.3%) and non-Hispanic whites (24.0%), compared to African-
Americans (20.8%) and Asians (18.7%). Similarly a higher proportion of non-Hispanic 
whites and Hispanics suffered from duplex identified superficial venous disease 13. 
 
Variation of the reported prevalence of varicose veins exists throughout all the major 
epidemiological studies. Robertson et al reviewed seven population studies and found a 
variation in prevalence from 6.8-39.7% in men and 24.6-41.7% in women 14. It is likely 
that a proportion of this variability could be accounted for by analysing the differing 
methods of reporting venous disease. Some studies included all evidence of disease from 
spider and reticular veins through to venous ulceration and some only included people with 
visible varicose veins. The methods of assessment of venous disease also varied; some 
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studies relied on self-assessment, others used questionnaires or examination by medical 
professionals. In spite of the variation in prevalence and geographical, ethnic or 
environmental factors, these studies demonstrated that varicose veins and venous reflux are 
a significant health issue throughout the world, especially when viewed at a population 
level.  
 
The sequelae of chronic venous insufficiency to the lower limb comprise of skin changes 
including venous eczema, haemosiderin deposition, lipodermatosclerosis and ulceration. 
The prevalence of ulceration, the most severe and difficult to treat form of chronic venous 
disease, is thought to be around 1% 15 ; this represents a significant number of affected 
individuals when considering the prevalence of venous disease in  the whole  population. 
 
1.1.3    Financial Implications of Venous Disease 
 
Healthcare providers often underestimate the magnitude and importance of chronic venous 
disease. Chronic venous disease is widespread and the treatment of more complex sequelae 
of chronic venous insufficiency, like venous leg ulcers, is not straightforward and requires 
long–term strategies. This results in a significant cost implication for healthcare providers 
and is estimated to command around 1% of western European healthcare budgets 16. There 
are approximately 2.5 million Americans suffering from venous ulceration with an annual 
calculated treatment cost of 1.6 billion dollars 17. A review of the burden of venous disease 
in Europe predicted that, in the United Kingdom (UK), approximately 77,000 varicose vein 
procedures should be performed annually in 2010 if aiming to treat all those with C2-6 
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CEAP classification 18,19 (please see Section 1.1.5 and Table 1.1.5.1 for the CEAP 
Classification);  in fact less than half this number of procedures were carried out. There has 
been a trend toward performing lessening numbers of venous procedures in the UK for 
some time 19. Previous National Institute for Health and Care Excellence (NICE) 
guidelines 20 recommended referral of patients with varicose veins causing troublesome 
symptoms or affecting quality of life along with those with more severe venous disease 
(old/current ulceration or bleeding). In spite of these recommendations, National Health 
Service (NHS) funding bodies commonly only reimburse treatment for patients with severe 
skin changes or a failure to respond to 6 months of compression treatment. It is the 
author/candidate’s expectation that the number of treatments in the NHS will slowly begin 
to increase in response to the more recent guidelines of 2013 21; the latter emphasise the 
importance of earlier intervention for venous disease to prevent  onset of the more costly 
and difficult to treat skin complications, thereby reducing overall costs to the NHS.  
 
1.1.4    Patient Perspectives of Varicose Veins – symptoms and quality of life 
Commonly described symptoms by sufferers of venous insufficiency are heaviness, 
swelling, itching, aching, restless legs, cramps and tingling 22. Several authors have noted 
that varicose veins are associated with poorer quality of life measures, both generic and 
disease specific23-25. Increasing scores in the clinical component of the CEAP classification 
(Section 1.1.5 and Table 1.1.5.1, below) relate to the proportion of people with any of the 
above-mentioned symptoms and correlate with symptom severity and quality of life 18 26 27. 
Although recent work by Darvall et al, agrees with the principle that both physical and 
psychological measures of generic quality of life are worsened by symptomatic lower limb 
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varicosities, this relationship did not correlate with increasing clinical severity as defined 
by CEAP 28. Chronic venous insufficiency is a degenerative, progressive condition and it is 
estimated that 2% of sufferers per annum progress from C2 to C3-6 disease 29, thereby 
suggesting that the quality of life of a significant proportion of the population will worsen 
and will involve a significant number of patients developing venous leg ulceration. 
 
1.1.5 Defining the Severity of Varicose Vein Symptoms and Using Symptoms to 
Commission Varicose Vein Interventions 
The symptoms as described above in 1.1.4 are often vague and difficult for the clinician to 
define. There are multiple tools to assess quality of life for completion by the patient, 
clinician or both. These can be generic (such as EuroQol-5D (EuroQol, Rotterdam, 
Netherlands) or Short Form-36 (Quality Metric, Lincoln, Rhode Island, USA)), with ability 
to assess the patient as a whole, but may underestimate the impact of specific disease 
states30, 31. These can be better assessed by disease-specific quality of life instruments 
(such as the Aberdeen Varicose Veins Questionnaire30 or Chronic Venous Insufficiency 
Quality of Life questionnaire32) however this does not allow direct comparison between 
different diseases. This ability to directly compare how a disease impacts on quality of life 
and measure the improvements after an intervention is important at a national health 
economic level where budgets are fixed and require rationing of interventions to maximise 
the improvement of the general population’s health.  
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Whilst there is good evidence for varicose veins negatively impacting quality of life as 
referenced in 1.1.4, it is difficult for the clinician (within the confines of an NHS 
consultation) to objectively and accurately assess the severity of symptoms upon a patient 
and compare patient to patient without recourse to time and resource heavy quality of life 
questionnaires.  
 
Varicose vein intervention commissioning occurs at a local/regional level with clinical 
commissioning groups.  There are 195 such groups across the UK, these are responsible 
for two thirds of the NHS budget and are independent of one another (www.nhscc.org).  
Pre- NICE Clinical Guideline 168 commissioning varied widely across the country33.  
Griffin’s work33 demonstrated that interventions were being rationed with differing groups 
commissioning interventions depending on whether varicose veins were mild, moderate or 
severe. This was defined using the CEAP classification (see section 1.1.6) – a 
classification tool unable to account for disease progression18.  A significant proportion of 
commissioners therefore utilised simple objective signs such as skin changes, to ration 
treatments and ensure treatments are not given to those misperceived to have a ‘cosmetic’ 
problem34. Sadly this approach would disadvantage a considerable number of patients 
whose venous symptoms were significantly affecting their quality of life, ignoring 
evidence that quality of life improvement after treatment is greater before skin damage 
develops and reduces recurrence35. 
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1.1.6    Classification of Chronic Venous Disease 
 
The classification of venous disease has developed significantly from the Basle 
Classification described in 1978 36. In 1994 the Clinical, Etiological, Anatomic, 
Pathophysiological (CEAP) classification was developed. This produced a score based on 
the severity of disease and was established to incorporate duplex ultrasonography 
assessment and allow comparison of outcomes across clinical studies 37. The system was 
revised in 2004 by Eklof 18 and has become the most widely used classification for venous 
disease. The CEAP classification is summarised in Table 1.1.5.1. 
Table 1.1.6.1    CEAP Classification (revised) 
Clinical Classification Etiological 
Classification 
Anatomical 
Classification 
Pathological 
Classification 
C0:  
Nil visible/palpable venous disease 
Ec: congenital As: superficial 
veins 
Pr: reflux 
C1:  
Telangiectasia or reticular veins 
Ep: primary Ap: perforator 
veins 
Po: obstruction 
C2:  
Varicose veins 
Es: secondary 
(post-
thrombotic) 
Ad: deep veins Pr,o: reflux and 
obstruction 
C3:  
Oedema 
 Pn: no venous 
pathology 
identifiable 
C4a:  
Pigmentation and eczema 
 
C4b:  
Lipodermatosclerosis and atrophie 
blanche 
C5:  
Healed venous ulcer 
C6:  
Active venous ulcer 
S: symptomatic: aching, pain, tightness, heaviness, skin irritation, muscle cramps etc. 
A: Asymptomatic 
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The CEAP classification is a useful means of assessment of venous disease at presentation, 
however, it correlates poorly with changes after treatment, particularly in C4-6 disease 38-41. 
The simplicity of CEAP allows its widespread adoption in healthcare since patient 
assessment is rapid and associates with little inter-observer variability. The Venous 
Clinical Severity Score (VCSS) 38 was developed by Rutherford and adapted by Vasquez 42 
as a supplement to clinical assessment by CEAP thereby allowing greater differentiation 
between disease states (particularly C4-6). The revised VCSS is shown in Table 1.1.5.2. 
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Table 1.1.6.2:  Venous Clinical Severity Score (revised) 
 None: 0 Mild: 1 Moderate: 2 Severe: 3 
Venous 
pain/discomfort 
 Occasional 
Daily-non 
limiting 
Daily-limiting 
Varicose Veins 
(diameter >3mm) 
 
Few scattered or 
corona 
phlebectatica 
Confined to calf 
or thigh 
Involving calf and 
thigh 
Oedema of venous 
origin 
 
Confined to 
foot/ankle 
Extends above 
ankle, below knee 
Extends to knee 
and above 
Skin pigmentation None/focal 
Limited to peri-
malleolar area 
Diffuse over 
lower 1/3 of calf 
Widespread above 
lower 1/3 of calf 
Inflammation (e.g. 
venous eczema, 
cellulitis) 
 
Limited to peri-
malleolar area 
Diffuse over 
lower 1/3 of calf 
Widespread above 
lower 1/3 of calf 
Active ulcer number 0 1 2 >3 
Active ulcer duration N/A <3 months 
>3months, <1 
year 
>1 year 
Active ulcer size 
(largest)(diameter in 
cm.) 
N/A <2 2-6 >6 
Use of compression 
therapy 
Not used 
Intermittent 
compliance 
Wears most days Full compliance 
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1.2  NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   
GUIDELINES 
1.2.1    Purpose of National Institute for Health and Care Excellence Guidelines 
The National Institute for Health and Care Excellence (NICE) is an executive body of the 
Department of Health functioning independently of the Department. It has responsibilities 
in four areas: 
• Health technology use 
• Clinical guidelines 
• Public sector worker guidance on health promotion and ill-health avoidance 
• Social care service and user guidance 
Appraisals are evidence based and examine efficacy and cost-effectiveness of interventions. 
Internationally, NICE guideline recommendations are highly regarded and influence health 
care systems worldwide. The guidance is designed to aid effective and cost-effective health 
care delivery to patients suffering from a variety of conditions.  
 
1.2.2    Development and Cost of Producing NICE Clinical Guidelines 
 
There are 172 currently extant clinical guidelines. Subjects for review are referred to NICE 
by NHS England. Production of each guideline involves a number of groups and 
individuals 43. The major groups and their tasks comprise:  
• NICE  
• Commissions guidelines 
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• Organises guideline development  
• Signs off of completed guidance 
• National Collaborating Centre  
• Drafts scope and review questions of guidelines (revised as each guideline 
is developed) 
• Provides technical and managerial support 
• Prepares draft and finalised guidelines 
• Advises NICE on publishing, dissemination, implementation and updating 
of guidelines 
• Guideline Development Group 
• Contributes to the scope of each guideline 
• Refines and agrees review questions 
• Discusses evidence leading to appropriate conclusions 
• Develops guideline recommendations 
• Supports and promotes guideline dissemination to clinicians 
• Patient and Public Consultation Group 
• Advises on patient and carer matters 
• Comments on draft guidelines from the patient/carer perspective 
• Aids with drafting public information sections of guidelines 
Guideline development is an exhaustive process and the above groups include managerial 
staff, public health staff, medical/healthcare professionals, statisticians, information 
technology experts and patient/carer groups. The process not only ensures that all 
available literature is reviewed and recommendations are clinically sound but also aims to 
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ensure guideline cost effectiveness. NICE measures cost effectiveness with ‘quality-
adjusted life years’ (QALY), a generic measure of disease burden in terms of quantity of 
life adjusted for quality of life. At present NICE recommends interventions (excluding 
cancer) at an incremental cost ceiling of <£20 000/QALY, although this may be raised if 
the available evidence is strong 44. 
 
The extensive and comprehensive process, along with the resources required predict that 
the development of NICE guidelines is likely to be expensive, at present there is no 
published data referencing the cost of producing each NICE clinical guideline.  
  
A ‘Freedom of Information Act’ (2000) enquiry as to the cost of producing NICE CG168 
was made (Appendix 1); however, NICE cannot provide an exact costing of guideline 
production. The corresponding information from NICE indicated that CG168 took 24 
months to produce (on average a guideline requires 26 months). NICE provided the 
National Collaborating Centre with £424 080 for the production of CG168, this figure 
does not include internal NICE costs, committee expenses or communication/press costs. 
Therefore the final figure is likely to be considerably higher than the approximately £0.42 
million for which NICE was able to account. 
 
The current and likely enduring climate of financial constraint makes it extremely 
important that NICE guidelines are useful to health professionals and to 
patients/families/carers in aiding decision-making and optimising care. Presently NICE 
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does not have the ability to measure the impact of its guidelines and specifically for NICE 
Clinical Guideline 168, assessment of the impact upon venous disease management has 
been entirely lacking. The work programme for this thesis included an attempt to assess 
the impact of NICE Clinical Guideline 168 on venous disease management at local and 
national levels in both primary and secondary care. 
 
1.3   COMPARISON OF INTERNATIONAL GUIDELINES ON VENOUS 
DISEASE 
1.3.1 Summary of National Institute for Health and Care Excellence Clinical 
Guideline 168 
 
The National Institute for Health and Care Excellence (NICE) Clinical Guideline (CG) 168 
was published in July 2013 and differed considerably from various sources of previous 
guidance for managing venous insufficiency. CG 168 recommended that adults (aged over 
18 years) be referred to a vascular specialist and undergo duplex ultrasound assessment if 
they suffered from symptomatic CEAP C2 varicose veins or worse. There was also a 
recommendation to refer patients suffering from leg ulceration that had not healed within a 
2 week period 21. Treatment guidelines also recognised that significant advances had been 
made in endovenous treatment modalities and that the treatment hierarchy should be 
amended to: 
1. Endothermal ablation 
2. Ultrasound-guided foam sclerotherapy (UGFS) 
3. Conventional surgery 
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Individual tailoring of treatment strategies (e.g., simultaneous or delayed treatment of 
tributaries or perforator treatments), is left to the specialist’s discretion, as evidence levels 
were not considered strong enough to produce ‘blanket’ guidance for treatment strategies – 
in any event NICE has stated that their guidelines are meant to be appropriate for ‘most’ 
patients but need individualised application [37]. CG168 specified compression hosiery as 
not considered adequate management for varicose veins unless ‘active’ interventional 
treatment was unsuitable. 
 
1.3.1.1    Venous Disease Guidance Prior to NICE CG168 
 
Prior to publication of CG 168 in July 2013 guidance on venous disease was limited 20. In 
general, it was recommended that patients with simple varicose veins (CEAP C2-3) (Table 
1.1.5.1) be treated conservatively with lifestyle advice and compression hosiery. If 
symptoms were very severe and affecting quality of life, then application could be made 
for special funding to allow further treatment. Only those patients with bleeding from 
varicose veins, skin damage (venous eczema, lipodermatosclerosis, haemosiderin 
deposition, healed or active ulceration) were thought to be suitable for referral to 
secondary care for vascular specialist review, interventional treatment funding was limited 
and variable across the UK as varicose vein surgery was seen as a ‘procedure of low 
clinical priority.’ This opinion prevailed in spite of clear evidence that symptomatic 
varicose veins significantly and negatively impact on patients’ quality of life. 
Conventional surgery was recommended as first line treatment for superficial venous 
reflux as evidence for newer endovenous techniques was limited although these procedures 
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could be performed providing special audit arrangements were in place to ensure their 
effectiveness.  
 
No recommendations were made regarding referral times for leg ulceration, which was 
primarily managed in the community by district nurses and general practitioners.  
 
1.3.2    Summary of European Venous Forum Guidelines 
 
The European Society for Vascular Surgery published guidelines on the management of 
chronic venous disease in 2015 45; these recommendations for diagnosis and assessment 
centred on clinical examination and duplex ultrasound. No guidance was offered on 
referral to vascular specialists from primary care or who should be treated for superficial 
venous disease. These considerations were left to attendant medical practitioners.  
Treatment recommendations suggested compression as the cornerstone of conservative 
management; there was limited evidence for veno-tonic medications their use being 
regarded as optional. Intervention was recommended for those with uncomplicated (CEAP 
C2-3) varicose veins. Reflux ablation recommendations were similar to NICE CG168, with 
a hierarchy of endothermal ablation, foam sclerotherapy and finally, surgery. The 
guidelines go slightly further than CG168 in recommending the consideration of foam 
sclerotherapy as a first line treatment in the elderly or frail. 
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In venous ulceration, compression bandages/hosiery were recommended as initial 
treatment, further investigation being required before superficial venous ablation could be 
considered as an aid to ulcer healing. 
 
1.3.3    Summary of American Venous Forum Guidelines 
 
American Venous Forum (AVF) guidelines were published in 2011 46. These did not 
address referral guidelines for specialist review as these are determined by medical 
insurance companies and are regularly reviewed and modified.   
 
In similarity with NICE, the AVF recommends all patients with varicose veins or more 
severe venous disease, should be assessed by a specialist and undergo duplex ultrasound. 
The AVF also recognises that compression alone is inadequate as a primary treatment of 
VVs in the presence of treatable superficial venous insufficiency. Medical treatment (e.g. 
with micronized purified flavonoid fraction) is suggested in those countries were this 
preparation is available.  
 
Recommendations for interventional treatment hierarchy are endothermal ablation over 
UGFS or surgical ligation/stripping.  The AVF recommended either UGFS or phlebectomy 
as treatment for tributaries.  Treatment of pathological perforating veins was advocated by 
the AVF if underlying healed or active ulceration were present.  
 
 
 
19 
Table 1.3.1:  Comparison of NICE vs EVF vs AVF Guidelines 
 NICE CG168 EVF AVF 
Community 
Referral Advice 
Yes No No 
Recommend 
Specialist Review 
For VV 
Yes Yes Yes 
Primary Imaging 
Recommendations 
Ultrasound duplex Ultrasound duplex Ultrasound duplex 
Compression Only if not suitable for 
intervention 
Only for 
conservative 
management 
Only if not suitable 
for intervention 
Medical Treatment Not 
recommended/available 
in UK 
Use is optional Can consider 
Intervention 1) Endothermal 
ablation 
2) UGFS 
3) Conventional 
surgery 
1) Endothernal 
ablation 
2) UGFS (consider 
as first line in 
elderly) 
3) Conventional 
surgery 
1) Endothermal 
ablation 
2) UGFS or 
conventional 
surgery 
Use phlebectomy 
of UGFS for 
tributaries 
 
1.4   PREDICTED CHANGES IN VENOUS TREATMENT ACTIVITY/COST 
 AFTER INTRODUCTION OF NICE CG168 
 
As part of the development of NICE CG168, NICE produced a costing report 47, estimating 
the expense of changing practice in contrast to the previous approach which restricted the 
use of superficial venous interventions. The costing report predicted an increase in referral 
rates by 25% and correspondingly, an increase in interventional procedures by 25%. This 
increased activity was equated with an additional £9000 per annum per 100 000 population. 
This increase in NHS expenditure was expected to be offset by the move to endovenous 
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procedures from conventional surgery with an expected cost saving of £7800 per annum 
per 100 000 population.  
 
The costing report predicted further benefits, including a reduction in incidence of venous 
leg ulcers. NICE calculated the resulting average cost of venous leg ulceration as 
£1872/elective in-patient admission. Further savings were predicted for primary care by 
the reduction of use of compression hosiery (estimated at £182 per year per patient).  
The savings anticipated from leg ulcer prevention and reduced use of compression hosiery 
were difficult to predict and were excluded from the overall conclusion that CG168 would 
result in increased expenditure of £1200 per annum per 100 000 population. 
 
The costing report differs from the health economic analysis where the cost-effectiveness 
compares costs in monetary units with outcomes in terms of their utility, usually to the 
patient, measured, e.g., in QALYs. This ensures treatments meet the willingness to pay 
threshold and allows measurement of the impact of the intervention on health and permits 
differing interventions in healthcare to be compared so that resources may be allocated 
more efficiently.  
 
NICE CG168 considered 4 treatments to be analysed for cost-effectiveness: 
1) Conventional surgery 
2) Endothermal ablation 
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3) Ultrasound-guided foam sclerotherapy 
4) Conservative management 
NICE found all treatments to be cost-effective compared to conservative treatment with 
lifestyle advice. Endothermal ablation provided the most improvement in quality 
associated life years but was associated with increased cost compared to UGFS. The 
incremental cost-effectiveness ratio of endothermal compared to UGFS was £3161 per 
QALY gained, both endothermal ablation and UGFS were considerably below the 
threshold to pay of £20 000 per QALY recommended by NICE21. 
 
1.5 Geographical Variation In Commissioning Of Varicose Vein Interventions 
With current budget constraints and need to save money, commissioners have often 
resorted to rationing treatment depending upon local financial plans. Three main strategies 
are employed to this end48 – rationing by: 
1. Withholding treatment until later disease state 
2. Rationing by delay 
3. Introduction of lifestyle criteria (e.g. BMI or smoking status) 
Differing CCGs are employing none, one or more of these strategies in attempts to save 
costs. This has resulted in significant geographical variation, related to differing 
commissioning policies across the UK49-52. 
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Chapter 2 
 
REVIEW OF EVIDENCE RELATING TO 
RECOMMENDATIONS OF NICE CG168 
 
NICE CG168 made several recommendations predicted to improve the management of 
venous disease in the UK; however, some aspects of CG168 were controversial especially 
the treatment hierarchy for VV: endothermal ablation (ETA), ultrasound-guided foam 
sclerotherapy (UGFS), surgery and compression hosiery 53. Here the evidence justifying 
this hierarchy and its support by the Vascular Society of Great Britain and Ireland 
(VSGBI) and the UK Royal Colleges of Surgeons (RCS) is examined.  
 
2.1 REVIEW OF LEVEL1 EVIDENCE FOR ENDOVENOUS TREATMENTS OF 
VARICOSE VEINS 
 
Search Strategy 
PubMed and OVID literature searches were performed from 1900 - April 2018 using the 
terms: RCT, sclerotherapy, radiofrequency ablation, laser ablation, endovenous and 
endothermal linked with varicose veins. Abstracts were screened and the full papers 
obtained if they compared UGFS with ETA for the treatment of VV. 
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Inclusion/Exclusion criteria 
Papers were included within the review if they were classified as randomised controlled 
trials, all other study types were excluded.  
Analysis 
ETA and UGFS RCT data were analysed in terms of endovenous methodology, technical 
success, clinical success, morbidity, complication rates, costs and time to return to work. 
 
PubMed and Ovid cite nine publications of data from five RCTs. The RCTs included 
Rasmussen et al 54-56, Lattimer et al 57, 58, Biemans et al 59, 60, Brittenden et al 61 and 
Venermo et al 62), all of which studied only great saphenous (GSV) VV. Only Rasmussen 
allowed recurrent GSV VV, provided the GSV was still present in the groin. Three papers 
described initial results 54, 57, 59 and were followed by further publications reporting longer-
term outcomes 55, 56, 58, 60. Rasmussen compared EVLA, RFA, UGFS and conventional 
surgery (CS) in 580 legs, Lattimer compared EVLA and UGFS in 100 legs, Biemans 
compared EVLA, UGFS and CS in 240 legs, Brittenden compared EVLA, UGFS and CS 
in 798 legs and Venermo   studied   EVLA and UGFS in 214 legs (Table 2.1.1).  
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Table 2.1.1: Comparison of RCT Allocated Treatments 
Trial Legs Randomised 
EVLA RFA UGFS CS Total 
Rasmusse
n 
2011 
144 148 125  
(124 received 
treatment) 
125  
(124 received 
treatment) 
580 
Lattimer 
2012 
50  
(4 lost to 
follow up) 
- 50  
(5 lost to follow up) 
- 100 
Biemans 
2013 
80  
(2 procedure 
failed) 
- 80  
(1 lost to follow up, 
2 other 
intervention) 
80  
(3 procedure failed, 
4 other intervention, 
8 no intervention) 
240 
Brittenden 
2015 
292  
(251 
completed 
follow up) 
- 212  
(183 completed 
follow up) 
294  
(236 completed 
follow up) 
798 
Venermo 
2016 
73 - 76  
(72 completed 
follow up) 
65 
(61 completed 
follow up) 
214 
 
EVLA-endovenous laser ablation, RFA-radiofrequency ablation, UGFS-ultrasound-guided 
foam sclerotherapy, CS-conventional surgery 
 
The details of treatment methods differed and are summarised for the controlled studies in 
Table 2.1.2. Brittenden’s multi-centre trial did not specify laser manufacturer, wavelength 
or fibre type presumably as these varied across hospitals. All of the other RCTs use bare-
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tipped fibres and lasers of varying wavelength: Rasmussen and Venermo used 980 and 
1470nm (Ceralas D, Biolitec, Jena Germany); Lattimer 1470nm (ELVeS Painless diode 
laser, Biolitec Inc, East Long Meadow, MA, 01028, USA); Biemans 940nm (manufacturer 
not specified). For most treatments the laser fibre appears to have been inserted into the 
GSV under ultrasound-guidance at approximately the level of the knee, or at the level of 
lowest incompetence in the thigh. The laser fibre tip was then advanced to within 2cm of 
the sapheno-femoral junction (SFJ) after which the GSV was ablated by slow withdrawal 
of the catheter. Rasmussen achieved a median of 69J/cm; Lattimer delivered a median of 
69J/cm, Biemans aimed for at least 60J/cm and Brittenden and Venermo’s studies aimed 
for at least 70J/cm energy delivery. This was in accord with previous work suggesting that 
at least 60J/cm energy delivery is required for satisfactory vein closure 63.  All of the RCTs 
used tumescence anaesthesia and some patients received light sedation. Rasmussen 54, 
Lattimer 57 and Venermo 62 performed EVLA with concurrent phlebectomies; Biemans 59 
with either concurrent or delayed (3 months) phlebectomies; and Brittenden 61 with UGFS 
to tributaries at 6 weeks (except one site that performed concurrent phlebectomies) 64. 
 
Only Rasmussen evaluated RFA and used a VNUS ClosureFAST catheter (Covidien, 
Mansfield, Mass, USA) inserted under ultrasound-guidance into the GSV just below the 
knee or at the lowest point of reflux in the thigh. This was performed using tumescent 
anaesthesia with light sedation and tributaries were removed with concurrent 
phlebectomies 54. 
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UGFS techniques varied considerably. Rasmussen inserted a single cannula into the GSV 
just below the knee and injected 3% polidocanol foam (volume not specified) until the 
foam was visualised by ultrasound at the SFJ and the GSV was contracted (in spasm) 
throughout its length 54. Lattimer inserted a single cannula into the GSV at knee level and 
injected 1% sodium tetradecyl sulphate (STS) using a median of 12ml/session. If the GSV 
was >8mm in diameter, tumescence anaesthesia was used to compress the vein before 
introduction of STS foam. Lattimer performed further foam treatments in 4.6% of patients 
who initially received EVLA and in 56% of the patients who had been randomised to foam. 
Biemans performed UGFS as per the Second European Consensus guidance 65 using 3% 
polidocanol with a maximum of 10ml/session. Six patients (4.6%) in the UGFS group had 
further foam treatment in the first six months. Brittenden did not provide information on 
use of cannulas (numbers and sites) but stipulated that 3% STS be used on truncal veins 
and 1% STS on varicosities 64, with a maximum of 12ml/session. At 6 weeks, 38% UGFS 
and 31% EVLA patients underwent a further UGFS treatment. Finally Venermo inserted a 
cannula in the proximal thigh and immediately below the knee and instilled either 1% 
polidocanol or 1/3% STS in unspecified volumes, allowing a further treatment at 4 weeks. 
All trials used foam volumes in accordance with manufacturers’ licences. For the RCTs 
including CS, SFJ ligation was performed and the GSV stripped to the knee, or just below, 
with concurrent phlebectomies. Rasmussen performed CS using tumescence anaesthesia 
under light sedation; Biemans used general anaesthetic; and Brittenden did not specify the 
type of anaesthesia. 
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Table 2.1.2: Comparison of Treatment Techniques 
Intervention 
 Study 
Rasmussen 
2011 
Lattimer 
2012 
Biemans 
2013 
Brittenden 
2015 
Venermo 
2016 
 
 
 
EVLA 
Fibre Bare tipped  
980-1470nm 
(Ceralas D) 
Bare tipped 
1470nm 
(ELVeS) 
Bare tipped 
940nm 
(Manufacturer 
not specified) 
No 
specification 
Bare tipped 
980nm 
Radial 
1470nm 
(Ceralas and 
ELVes) 
Cannulation All studies – GSV under ultrasound guidance at level of knee or lowest point of reflux, 
advanced to 2cm from SFJ 
Energy 69J/cm 69J/cm >60J/cm >70J/cm 70J/cm 
Anaesthesia All studies – tumescence analgesia +/- light sedation 
Tributaries Concurrent 
phlebectomies 
Concurrent 
phlebectomies 
Concurrent or 
delayed (3 
months) 
phlebectomies 
UGFS at 6 
weeks (1 
centre 
concurrent 
phlebectomies) 
Concurrent 
phlebectomie
s 
 
 
RFA 
 VNUS, 
cannulation just 
below knee 
GSV or lowest 
point of reflux 
with concurrent 
phlebectomies, 
under 
tumescence 
analgesia 
- - -  
 
 
 
UGFS 
Sclerosant Polidocanol Sodium 
Tetradecyl 
Sulphate 
Polidocanol Sodium 
Tetradecyl 
Sulphate 
Polidocanol 
and Sodium 
Tetradecyl 
Sulphate 
Concentration 3% 1% 3% 3% truncal, 1% 
to varicosites 
PD 1% 
STS 1 and 
3% 
Volume Not specified Median 
12ml/session 
Maximum 
10ml/session 
Maximum 
12ml/session 
Not specified 
Technique Single cannula 
just below 
knee. Continue 
injection until 
foam visualised 
at SFJ and GSV 
contracted 
Single cannula 
at knee level. 
If GSV>8mm 
then 
tumescence to 
reduce 
diameter 
As per 2nd 
European 
Consensus 
No 
specifications 
regarding 
number of 
injections/sites 
Cannula 
proximal 
thigh and 
immediately 
below knee 
 
 
 
28 
2.1.1    Technical Success 
Rasmussen defined technical success as a closed or absent GSV without reflux and failure 
as an open segment of GSV >10cm in length or GSV unsuccessfully stripped. Five GSVs 
were open after one month in the UGFS group and these were re-treated. At one year 
(2011), the technical failures rates were 16.3% for UGFS, 5.8% for EVLA and 4.8% for 
RFA (p<0.001, χ2) 54; and at 3 years (2013) they were 26.4% for UGFS, 6.8% for EVLA 
and 7% RFA (p <0.0001, statistical test not stated) 55.  
 
Lattimer defined technical success as complete ablation of GSV reflux (occlusion not 
required) and failure as reflux anywhere in the above knee GSV. At 3 months (2012), the 
technical success rate, as defined by absence of above knee GSV reflux on duplex, was 
80% in both the EVLA and UGFS groups; at 15 months (2013), global absence of reflux 
was 41% for EVLA and 43% for UGFS. At 15 months (2013), however, complete GSV 
occlusion was observed in 95.5% of the EVLA, and 67.4% of the UGFS, patients (p=0.001, 
Fisher exact probability test). 
 
Biemans defined technical success as complete obliteration, without flow or reflux, of the 
mid-thigh GSV. At 12 months (2013), the technical success rate was 88.5% for EVLA and 
72.7% for UGFS (p <0.001, χ2). 
 
Brittenden (2015) defined technical success according to Kundu 66 as ‘successful ablation 
of the target vein as demonstrated by a complete lack of flow or disappearance of vein by 
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duplex ultrasound imaging in the entire treated segment.’ At 6 weeks, the technical success 
rate was 83% for EVLA and 54.6% for UGFS (p <0.01, statistical test not stated). 
Venermo (2016) measured 1-year occlusion rates (no further information) and diameter of 
GSV 20cm below the groin pre and post treatments; one-year results were 97% for EVLA 
and 51% for UGFS (p<0.001). 
 
2.1.2    Clinical Success 
Rasmussen reported clinical success using the Venous Clinical Severity Score (VCSS) 42, 
Aberdeen Varicose Vein Questionnaire (AVVQ) 30, Short Form-36 (SF-36®) (Quality 
Metric, Lincoln, Rhode Island, USA) and visual analogue scores (VAS) for pain. All three 
improved significantly in all four patients groups and there was no difference between 
EVLA, RFA, UGFS and CS at 1 (2011) or 3 years (2013). 
  
Lattimer (2013) reported clinical success using the VCSS, AVVQ, and the Saphenous 
Treatment Score 67. All three improved significantly in both groups and there was no 
difference between EVLA and UGFS recorded to 15 months; although 7-day pain scores 
were significantly higher with EVLA. 
 
Biemans (2013) reported clinical success using the Chronic Venous Insufficiency Quality-
of-Life Questionnaire (CIVIQ) 32 and EuroQoL 5D (EQ-5D) (EuroQol, Rotterdam, 
Netherlands). These both improved at 3 months and there was no difference between 
EVLA and UGFS recorded to one year.  
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Brittenden (2015) reported clinical success using AVVQ, VCSS, EQ-5D, SF-36 and 
clinical vein appearance. At 6 months both EVLA and UGFS showed improvement in 
AVVQ and VCSS, with no statistical difference between EVLA and UGFS reported. Both 
EQ-5D and the physical component of SF-36 showed improvement in all groups, with no 
statistical difference between groups. The SF-36 mental component was slightly better in 
EVLA vs. UGFS (p=0.048, using general linear model with adjustments for covariates 
used in minimisation algorithm) and all groups improved. Patient and nurses reported no 
difference between UGFS and EVLA in terms of residual veins at 6 weeks but fewer 
residual veins were reported by patients (not by nurses) in EVLA compared to UGFS at 6 
months. Venermo’s (2016) clinical success was measured using AVVQ and showed 
improvements in all groups with no statistical differences between groups. 
 
2.1.3    Morbidity and Complication Rates 
Morbidity and complication rates were very low in all RCTs in all treatment groups. 
Rasmussen (2011) reported one iliac vein thrombosis with pulmonary embolus one week 
after UGFS. Lattimer (2012) reported no serious complications except one EVLA patient 
who developed a common femoral vein thrombosis. Biemans (2013) noted a low 
frequency of minor morbidity (such as hyperpigmentation, thrombophlebitis and 
paraesthesiae), which was not statistically significant between groups. Brittenden (2015) 
reported no difference between groups in terms of serious adverse events (these included 
deep vein thrombosis and pain). Venermo (2016) noted no serious complications but 
recorded haematoma in 42% EVLA and 20% UGFS (p=0.001) and 4% superficial wound 
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infection rate with EVLA. Skin pigmentation and palpable lumps were seen more 
commonly in UGFS than EVLA at 4 weeks.  
 
2.1.4    Costs and Return to Work 
Only Rasmussen (2011), Lattimer (2012), Brittenden (2015) (reported by Tassie 68) and 
Venermo (2016) looked at these outcomes. Rasmussen reported a quicker return to work 
after UGFS and RFA when compared to EVLA and Venermo found UGFS resulted in a 
faster return to work than EVLA. Treatment costs were €994 for UGFS, €1360 EVLA and 
€1436 RFA (cost of catheter higher than for EVLA). If time lost from work is included 
overall costs were €1554 UGFS, €2200 EVLA and €1996 RFA. Lattimer also found a cost 
advantage with UGFS (£230.24) compared to EVLA (£724.72), even if further foam 
treatments were required. Brittenden’s trial demonstrated treatment costs of £245 for 
UGFS and £737 for EVLA (the difference appears to be due in part, to increased 
consumable costs). At 6 months total health service costs (including follow up and 
unplanned use of health service), UGFS costs were £465 and EVLA were £975. 
 
2.1.5    Five-Year Results 
Both Rasmussen’s (2017) 56 and Biemans’ (2015) 60 groups have reported 5 year outcomes.  
Rasmussen had a significant loss to mid-term follow up with only 223 of the initial 580 
legs available for 5-year review. GSV occlusion/absence was noted in 68.4% of UGFS and 
93.2% of legs in RFA and EVLA on duplex, however, clinically apparent recurrence was 
noted in 18.7% RFA, 38.6% EVLA and 31.7% for UGFS. Biemans’ team evaluated 193 of 
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224 initially randomised legs when Kaplan-Meier estimates demonstrated GSV 
obliteration in 77% of EVLA and 23% of UGFS legs; however, freedom from additional 
treatments over the 5-year period showed no difference between EVLA and UGFS. This 
perhaps illustrates the importance of technique (Biemans used approximately half the 
volume of foam compared with Rasmussen’s study) to ensure improved long-term 
outcomes with UGFS when techniques are compared across case series 69. 
  
Rasmussen did not study patient reported outcome measures at 5 years, however Bieman’s 
group did perform this analysis. They found CIVIQ scores statistically worsened for UGFS 
(0.98 increase per year, 95 per cent CI 0.16 to 1.79) and improved for EVLA at 5 years 
(−0.44 decrease per year, 95 per cent CI −1.22 to 0.35), however, EQ-5D improved 
slightly (EVLA: 0.02, CI; 0.01, 0.03 and UGFS: 0.01 CI; 0.01, 0.02) and EQ-VAS 
worsened slightly in all groups. Multivariable analysis including age of CIVIQ, EQ-5D 
and EQ-VAS scores demonstrated no statistically significant differences between EVLA 
and UGFS. 
 
2.1.6    Status Of Level - 1 Evidence and CG168 
Clearly the sources of level-1, RCT evidence are limited by variation in technique, 
equipment details, definition of technical versus clinical success/failure, extent and 
duration of patient follow-up, relatively sparse use of patient reported outcomes and costs. 
Importantly, patient variation did not reflect daily UK practice since only primary GSV 
disease was studied in all RCTs. Reassuringly, all studies demonstrated good safety 
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[65,66] and efficacy was clinically measurable with statistically confirmed improvement in 
venous disease. 
 
In terms of improvement in patients’ wellbeing, ETA and UGFS seemed similar with 
similar PROMS and low complication rates; however, the CG168 hierarchy was supported 
by the consistently greater technical success with ETA relative to UGFS. UGFS was 
reproducibly less expensive than ETA.   
 
2.2  OBESITY AND CHRONIC VENOUS INSUFFICIENCY DISEASE 
 
There is increasing evidence linking obesity and chronic venous insufficiency independent 
of the risk of venous thromboembolism (VTE) as a cause as reviewed below. Obesity is 
clearly a complex disease process demanding several disease-related considerations for 
any treatment modalities in people suffering from this serious condition. NICE CG168 
does not make any recommendations specific to venous disease in obesity except advising 
weight loss as part of lifestyle measures; the extant literature however demonstrates the 
link between obesity and venous disease and raises a number of questions pertinent to 
venous disease and its management in relation to CG168 in people with both conditions. 
As the evidence for the relationship between obesity and venous disease builds and the 
observed increase in incidence of obesity continues, perhaps updated guidelines will go 
further in making recommendations for the suitability of treatment methods for superficial 
venous disease in obese people. Incorporating this evidence into future guidelines will 
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inform clinicians and policy makers alike in commissioning interventions for obese 
patients. 
 
2.2.1    Epidemiology of Obesity 
The World Health Organisation (WHO) defines obesity as a Body Mass Index (BMI) 
>30kg/m2 70. In the UK levels of obesity have steadily risen from 1993 to 2012, from 
13.2% to 24.4% (men) and 16.4% to 25.1% (women) 71. Worldwide, the WHO reports 
there are approximately 2.8 million deaths annually as a result of excess body weight and 
in 2008, 10% of men and 14% of women were classified as obese (approximately double 
the prevalence in 1980). Rates of obesity were highest in the Americas with a 26% 
prevalence of obesity with slightly lower prevalence of 23% in Europe 72.   
 
The Health Survey England (HSE) 2012 73 work found a strong relationship between age 
and obesity. Correspondingly, rates where 12% males and 14% females aged 16-24, rising 
to 33% of men and women aged 65-74 but the prevalence then decreases to 19% men and 
18% women aged greater than 85.  
 
Income also appears to affect obesity; rates were lowest in higher (first quintile) income 
groups (21% men and 19% women) and highest in the fourth quintile (27% men and 33% 
women). This relationship appeared strongest in females.  
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Geographically, in the UK, age-standardised measurement of adult obesity did not vary 
significantly by region; however, by the inclusion of all those categorised as overweight 
(i.e. all those with BMI>25), in men, London was found to have the lowest rate (58%) and 
the West Midlands the highest (73%). In regard to women, London again displayed the 
lowest prevalence (51%) with the rest of the UK exhibiting similar levels of obesity five of 
the nine regions ranged from 60-61%. 
 
Little data is available regarding the variation of obesity in differing ethnic groups. HSE 
produced a ‘boosted sample’ from minority ethnic groups in its 2004 survey, which was 
assimilated into the National Obesity Observatory (NOO) part of the Public Health 
England report of 2011 74. Figure 2.2.1 demonstrates that rates of obesity by ethnicity vary 
greatly depending upon the measure of obesity used (BMI>30, waist: hip ratio or waist 
circumference >102cm). 
Figure 2.2.1: BMI, Waist: Hip Ratio And Waist Circumference, Men, England 
Reproduced From NOO Report: 
Obesity and Ethnicity, 2011 
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The current trend is predicted to continue with an on-going increase in population levels of 
obesity. Evidence is plentiful in support of decreased energy expenditure and increased 
calorie intake as a cause for the epidemic of obesity 75-77. 
 
2.2.2    The Pathogenesis of Obesity 
The aetiology of obesity is a complex interaction between environmental, hormonal and 
genetic influences. Environmental factors include the influence of increasing portion size, 
parallel with the increase in the obesity epidemic 78. There is also a preponderance of 
increasing dietary fat content 79, 80 and high-energy foods that do relatively little to supress 
appetite whilst contributing towards greater daily calorie intake. The convenience of 
modern day living also encourages a sedentary lifestyle, thus decreasing energy 
expenditure 80-82. Therefore, there is a trend towards increased energy consumption with 
decreased energy expenditure. 
 
Multiple hormones have been implicated in obesity. These hormones can be centrally 
derived, gut-related or from adipose tissue itself. Hormones involved in obesity that are 
centrally derived include growth hormone and other components of the hypothalamo-
pituitary-adrenal axis 83 as well as complex pathways for controlling energy homeostasis in 
the hypothalamus 84. Ghrelin, a peripherally acting, stomach-derived hormone acts to 
increase appetite 85. Other gut hormones act as anorectic agents, limiting food intake and 
allowing optimal digestion and absorption. These include cholecystokinin 86, peptide YY 87, 
pancreatic polypeptide 88, oxyntomodulin  89 and glucagon-like peptide 1 90. Appropriate 
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balance between appetite stimulating and suppressing influences obviously avoids the 
problems linked with overfeeding such as hyperinsulinaemia and insulin resistance.  
 
Adipokines are a collection of hormones produced by adipocytes. These include tumour 
necrosis factor-α   (TNF-α), interleukin-6 (IL-6), leptin and adiponectin. These hormones 
act both centrally, reducing appetite and regulating energy expenditure, as well as 
peripherally to affect insulin sensitivity, oxidative capacity and lipid uptake. It is the action 
of these hormones that is thought to be responsible for metabolic disturbances resulting in 
insulin resistance, type 2 diabetes and related cardiovascular disease 91, 92. 
 
Genetic influences can be divided into syndrome associated obesity (e.g. Prader-Willi) and 
non-syndromic obesity. The heritability of non-syndromic obesity appears to be in the 
range of 40-70% 93. Over the last few years the ‘human obesity gene map’ has described 
11 single gene mutations, 50 loci related to Mendelian syndromes and 127 candidate genes 
related to obesity and numerous obesity-related genes have been described in animal 
models of obesity 94. A full understanding of the genetic preponderance of obesity must 
await further research. Thus the pathophysiology of obesity is complex and multi-factorial. 
The effects of obesity are widespread and result in greater problems than just an increase in 
physical size.  
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2.2.3    Measures of Obesity 
BMI (weight divided by height squared) is a commonly used method of indirectly 
assessing obesity. It can be calculated by measures easily made in most clinical settings. 
Height and weight, however, do not necessarily reflect body fat content exactly as body fat 
increases and muscle mass decreases with age (giving a falsely low BMI) and athletes with 
a large muscle mass (but low body fat) may have an elevated BMI. Other methods of 
estimating body fat include dual-energy x-ray absorption and impedance-based techniques. 
Whilst these are likely to be more accurate, their expense and impracticalities make them 
unsuitable for routine practice. Despite its inaccuracies, BMI is a strong predictor of risk 95 
and therefore is the most commonly used measure of obesity in clinical practice. 
 
2.2.4 Search Strategy 
A Medline/PubMed (from 1946-2015) and Cochrane library literature search was 
conducted for articles related to obesity, overweight, thrombosis, varicose veins. These 
terms were linked with intra-abdominal pressure, inflammation, haemodynamics, CEAP 
(Clinical, aEtiology, Anatomy, Pathology classification of VVs), CVI, treatment, 
endovenous, endothermal, sclerotherapy, bariatric surgery, VTE, deep vein thrombosis 
(DVT). Further articles were located by following citations in previously identified papers. 
 
2.2.5    Obesity and Superficial Venous Reflux Disease 
A significant number of epidemiological studies have reported obesity to be a risk factor 
for the development of VV, chronic venous insufficiency and leg ulceration (Table 2.2.1).  
 
 
 
39 
2.2.6    The Effect of Obesity on Lower Limb Venous Haemodynamics 
Obesity 96-98, and other factors which increase intra-abdominal pressure (IAP) (as 
measured and validated by Iburti et al 99, 100) 101 102, are associated with increased femoral 
vein pressure and diameter 96, 97, 103 and decreased femoral vein flow leading to lower shear 
stress 102, 104 and possibly, increased predisposition to inflammation 15. While in some 
young and otherwise fit people this increase in venous outflow resistance maybe 
compensated by improved calf muscle pump function 105, in the immobile and the elderly, 
these features are likely to favour the development and progression of lower limb venous 
disease (LLVD). 
 
2.2.7    Obesity and The Symptoms and Signs of Lower Limb Venous Disease 
Symptoms suggestive of LLVD are common in the overall adult population; however, 
there is an inconsistent relationship between these symptoms and presence of venous 
disease on objective clinical and duplex ultrasound examination 106. This suggests that 
other factors, such as obesity, may be important in the aetiology of such “venous” 
symptoms 103, 107. Correspondingly, obesity appears to be associated with a worse CEAP 
clinical grade in patient cohorts 103, 108-112 and epidemiological studies 113 whilst patients 
with skin changes 103 and active venous ulceration are more likely to be obese 114. 
 
2.2.8    ‘Diabesity’ and Lower Limb Venous Disease 
No confirmed link exists between diabetes mellitus and varicose veins but there is a strong 
correlation between obesity and diabetes embodied in the term ‘diabesity’ 115. In patients 
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who develop venous ulceration, diabetes is likely to impair wound healing and prolong 
ulcer duration 116. There is no extant evidence that obesity is an independent risk factor for 
LLVD ulceration; however, given the ‘pro-inflammatory’ state in diabetes (along with 
obesity) and that obesity is a risk factor for LLVD, this link would appear likely. 
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Table 2.2.1: Cohort Studies: Relationship Of Obesity And Varicose Veins. 
Author Year Journal Number of 
Participants 
Relationship with obesity 
Mekky et al8 1969 Brit Med J 971 women Increasing body weight correlated with 
prevalence of varicose veins (P<0.001) 
Abramson et 
al11 
1981 J Epidemiol 
Com Health 
4888 Those with VV tended to be heavier –
mean difference 3.8kg (P<0.00001) 
Ducimetiere et 
al117 
1981 Int J Epidemiol 7432 men VV positively associated with increased 
BMI (P=0.001) 
Seidell et al118 1986 Am J Pub 
Health 
19126 In women raised BMI associated with VV 
(OR 3.06; 95% CI 2.03-4.62 in severely 
overweight) 
Brand et al7 1988 Am J Prev Med 3822 Women with VV more likely to be obese 
(P<0.01) 
van Noord et 
al119 
1990 Int J Epidemiol 11825 women Quintiles with BMI<27.93 less likely to 
have VV (P<0.05) 
Stvrtinova et 
al120 
1991 Int Angiol 696 women Patients with VV more likely to be obese 
(P<0.05) 
Sadick et al121 1992 J Dermatol Surg 
Oncol 
500 women Raised BMI is risk factor for VV 
Sisto et al122 1995 Eur J Surg 8000 Raised BMI associated with VV 
Scott et al123 1995 J Vasc Surg 335 Obesity increases risk of CVI (OR 
1.06/kg/m2; 95% CI 1.01-1.1; P=0.014) 
Canonico et 
al124 
1998 Angiol 1319 Raised BMI associated with increasing 
prevalence of VV (P<0.0001) 
Kontosic et 
al125 
2000 Acta Med 
Okayama 
1324 Raised BMI associated with VV (OR = 
1.04; 95% CI 1.01-1.07) 
Iannuzzi et 
la126 
2002 J Vasc Surg 104 women BMI >30 associated with VV (OR = 5.8; 
95% CI 1.2-28.2) 
Maurins et 
al127 
2008 J Vasc Surg 3072 BMI > 30 associated with more superficial 
reflux 
Robertson et 
al6 
2013 Eur J Vasc 
Endovasc Surg 
880 Risk of developing reflux if overweight 
(OR = 2.1; 95% CI 1.0-4.4) 
Vlajinac et 
al112 
2013 Eur J Vasc 
Endovasc Surg 
1116 Obesity related to ‘C’ category of CEAP 
(multivariate analysis, P<0.001) 
VV – varicose veins, BMI – body mass index, CVI – chronic venous insufficiency 
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2.2.9    Treatment of Lower Limb Venous Disease in Obese People.  
Obesity is associated with delayed healing of chronic venous ulceration and increased risk 
of ulcer recurrence 107 following treatment with compression compared with ‘normal 
weight’ patients 128. The reasons for this probably include, in obese people, the increased 
technical difficulty in applying adequately sustained compression, immobility, poor 
compliance, and the adverse venous haemodynamics described above. Obese people are 
more prone to anaesthetic 129 and surgical morbidity, such as surgical site infection 114 and 
mortality 130, 131; additionally, venous surgery may be technically challenging in the obese 
leg. The same may be true of endovenous techniques although, as obese patients are 
notably absent from many of the published trials, it is difficult to draw any firm 
conclusions 132-135. Similarly, some 136-138, but not all studies 139, have found obesity to be 
associated with increased treatment failure/varicose vein re-canalisation. 
 
2.2.10    Treatment of Obesity in Patients With Lower Limb Venous Disease 
Bariatric surgery, comprising either Roux-en-Y gastric bypass (up to 80% of patients 
improve) 140 or vertical band gastroplasty (up to 100% patients improved) 141 has been 
shown to lead to an improvement in the symptoms and signs of LLVD.  This may be due 
to an improvement in the adverse haemodynamics associated with obesity 104.  Although 
level 1 evidence is lacking, whenever possible, it would seem appropriate to try to manage 
obesity before embarking upon traditional surgical or endovenous treatment of LLVD.  
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2.2.11    A Reflective Approach to Venous Disease in People Suffering Obesity 
Evidence of obesity as a risk factor for venous disease has been well documented by 
numerous epidemiological studies. Table 2.2.1 illustrates the many studies linking obesity 
and venous disease; the correlation appears mainly between BMI and VV in older 
manuscripts and between BMI and chronic venous insufficiency in more recent 
publications. Perhaps this is a reflection of the increased understanding of both obesity and 
LLVD as inflammatory conditions rather than simply a combination of excess adipose 
tissue and superficial venous reflux? The literature demonstrates that obesity worsens the 
symptoms of LLVD and is related to a worse CEAP score. These features may result from 
the venous haemodynamic changes found in several studies, but may also be compounded 
by a degree of ‘functional’ venous insufficiency as a result of obese patients’ poor mobility 
and lack of activation of the calf muscle pump. Venous ulceration is likely to be more 
common and when present has been linked to reduced healing rates. The latter is 
particularly true of diabetic, obese patients. Obesity is a complex disease process, which is 
not yet fully understood. As such the aetiology of combined excess body fat and LLVD or 
‘phlebesity,’ is further still from being understood. With more severe symptoms and 
greater risk of ulceration, perhaps obese patients present a greater degree of clinical 
urgency in their need for definitive VV treatment? 
 
Treatment of LLVD in the obese is an area where definitive evidence is truly lacking. 
Whilst endovenous techniques are likely to be safer, they are also likely to be technically 
more difficult than in normal weight patients; post -treatment compression is more difficult 
to apply. The durability of treatment methods has not been examined raising questions of 
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whether re-canalisation is more likely because of higher femoral vein pressure or does 
there exist the potential for higher rates of VTE? Along with the former considerations 
there are many other unanswered questions. Perhaps it is more prudent for patients to first 
undergo weight-loss management programmes/surgery, which has been demonstrated to 
improve their LLVD symptoms before undergoing venous interventions, the latter could be 
used subsequently if still required? 
 
VTE is more prevalent in the obese and even normal weight diabetic patients suffer a more 
complicated clinical course. No clinical scoring system for VTE has been separately 
validated in the obese, therefore diagnosis can be clinically challenging. Confirmatory 
imaging of flow and compressibility by DUS is technically demanding due to the depth of 
the deep veins. Diagnostic imaging may be improved with cross-sectional techniques, 
however this is more ‘resource-heavy’ and further research into the reliability of CT and 
MRI venous imaging in obese people seems required?  
 
2.2.12  Obesity, Venous Disease and NICE Guidance CG168 
LLVD and obesity have both increasingly common around the world. As such, surgeons or 
phlebologists will be treating ever-greater numbers of obese patients with LLVD. 
Furthermore, clinicians in many other specialties are going to be treating a wide range of 
obesity-related health problems in people who also have, or are at risk of developing 
LLVD, and complications including deep vein thrombosis (DVT).  Unfortunately, obese 
people have been specifically excluded from many, if not most, of the pivotal studies. As 
such, many basic questions remain unanswered and there is an urgent need for further 
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research in this area and further development of NICE guidance using what evidence is 
currently available although some may argue that the currently available data are not 
strong enough to make any recommendations? Presently, clinicians are left with the task of 
advising venous treatments based primarily upon clinical judgement supplemented by 
adjuring people to use lifestyle modification with weight loss to improve symptoms as well 
as general health. 
 
As discussed above, CCGs are using ‘lifestyle’ rationing (based on BMI or smoking status) 
to reduce costs.  Significant proportions of CCGs are applying these measures to VV 
interventions142. With the absence of evidence at present to inform NICE guidance 
regarding obesity and venous disease, it is perhaps unsurprising that no guidance is offered 
over weight loss as a lifestyle measure in VV.  This prevents vascular specialists from 
challenging this behaviour.  With the accumulation of evidence and its incorporation, 
future guidance will inform both clinicians and commissioners alike. 
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Chapter 3 
RESULTS 
 
OVERVIEW AND HYPOTHESES TESTED 
 
Sections 3.1-3.3 describe the impact of CG168 upon a local secondary care vascular unit 
by comparing 18-month periods before and after July 2013 when the guidelines were 
introduced. The data presented centres upon sections of the guidelines directly appropriate 
to vascular surgeons in Sections 3.1 and 3.2; Sections 3.3, 3.4 and 3.5 show evidence of 
the effects of CG 168 on the general practice/vascular surgical interface, 3.3 and 3.4/3.5 at 
local and national levels, respectively. Changes of varicose vein management in local 
secondary care are reported in section 3.1. Evidence for any improvement in the secondary 
care management of leg ulcer patients is related in Section 3.2.  Local referral patterns 
from general practice generated the data for Section 3.3 to find if CG 168 had affected 
access to specialist care in relation to social deprivation. 
 
Section 3.4 and 3.5 present the data from The Health Improvement Network (THIN) 
database to try to delineate the national impact of CG168 on general practice and its 
influence upon the practice of vascular surgery with Sections 3.4 and 3.5 focusing on 
simple venous disease (varicose veins) and venous leg ulceration, respectively. 
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Hypotheses Tested By Section: 
3.1         Introduction of NICE CG168 at HEFT has resulted in increased numbers of 
varicose vein interventions. These will be performed at an earlier CEAP stage and 
using an increasing number of endovenous modalities.  
        Null hypothesis – introduction of CG168 has not affected VV interventions.  
 
3.2 Introduction of NICE CG168 at HEFT has increased the number of leg ulcer 
referrals. Leg ulcers will be referred earlier. 
        Null hypothesis – introduction of CG268 has resulted in no change in leg ulcer 
referrals. 
 
3.3  Introduction of NICE CG168 has increased number of referring GP practices. 
There has been no change in access to specialist care relating to social deprivation. 
 Null hypothesis – NICE CFG168 has not increased the number of GP practices 
referring patients and has adversely affected access to specialist care related to social 
deprivation. 
 
3.4 Introduction of NICE CG168 has improved the numbers of patients referred with 
varicose veins by primary care. There has been a reduction in prescription of 
compression hosiery and more varicose vein interventions are being performed. 
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 Null hypothesis – NICE CG168 has not increased varicose vein referrals or affected 
compression hosiery prescription/varicose vein interventions. 
 
3.5 Introduction of NICE CG168 has increased the number of leg ulcers referred by 
primary care nationally. 
 Null hypothesis – NICE CG168 has not affected referrals for patients diagnosed 
with leg ulcers in primary care 
 
3.1 CHANGES IN VARICOSE VEIN TREATMENT ACTIVITY AFTER 
INTRODUCTION OF NICE CG168 IN EAST BIRMINGHAM  
 
NICE CG168 declared that patients with symptomatic varicose veins should receive NHS 
treatment and that waiting for skin changes to develop was inappropriate. CG168 also 
introduced a treatment hierarchy for superficial venous disease. The clinical data presented 
below aimed to assess the impact of these components of CG168 on local (Heart of 
England NHS Foundation Trust) (HEFT) secondary care management of varicose veins.  
 
3.1.1 Abstract 
• Objective: Although varicose veins (VV) are a common cause of morbidity, the 
UK National Health Service (NHS) and private medical insurers (PMI) have 
previously sought to ration their treatment in order to limit health care expenditure 
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and reimbursement but this approach was lacking an evidence base. The July 2013 
UK National Institute for Health and Care Excellence (NICE) Clinical Guidelines 
(CG168) embodied the promotion of evidence-based commissioning and 
management of VV. The aim of this study was to evaluate the impact of CG168 on 
the referral and management of VV at the Heart of England NHS Foundation Trust 
(HEFT), Birmingham, UK. 
 
• Methods: Interrogation of the HEFT Performance Unit prospectively gathered 
database, yielded numbers of patients undergoing interventions for VV from 1 
January 2012 to 31st December 2014. Patients treated before (group 1) and after 
(group 2) publication of CG168 were compared. 
 
• Results: There were 253 patients, 286 legs (48% male, mean [range] age 54 and 
[20-91] years) treated in group 1 and 417 patients, 452 legs, (46% male, mean 
[range] age 54 and [14-90] years) treated in-group 2, an increase of 65%.  CG168 
was associated with a significant reduction in the use of conventional surgery (131 
patients [52%] group 1 vs. 127 patients [30%] group 2, p=0.0003, χ2), no change 
in endothermal ablation (30 patients [12%] group 1 vs. 45 patients [11%] group 2), 
a significant increase in ultrasound guided foam sclerotherapy (92 patients [36%] 
group 1 and 245 patients [59%] group 2, p=0.0001, χ2), and an overall increase in 
treatment for CEAP class C2/3 disease (53% group 1 and 65.2% group 2, 
p=0.0022, χ2). 
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• Conclusions: Publication of NICE CG168 has been associated with a significant 
increase (65%) in the number of patients treated, referral at an earlier (CEAP class 
C) stage and increased use of endovenous treatment.  CG 168 has been effective in 
improving access to, and quality of care, for VV at HEFT.  
 
3.1.2    Introduction  
Varicose veins (VVs) are common in the adult population 6 causing considerable morbidity, 
disability and loss of productivity 25, 46, 143-145. Previous local, regional and national 
guidelines, such as those published by the UK National Institute for Health and Care 
Excellence (NICE) in 2001, discouraged referral and interventional treatment for VV 146. 
Instead, this earlier guidance advocated conservative management in primary care with 
advice on exercise, leg elevation and compression hosiery and indicated that referral to 
secondary care was only required for specialist assessment. Interventional treatment was 
reserved mainly for those patients who had bled from their VV, had active ulceration or 
skin changes, or who had suffered repeated bouts of thrombophlebitis. Patients suffering 
from ‘severe’ VV symptoms could be referred but treatment was only funded if their VVs 
were judged as causing a ‘significant’ impact on their quality of life. The overall low 
clinical priority placed on the treatment of VV by NICE and other bodies encouraged the 
UK National Health Service (NHS) and private medical insurers (PMI) to ration treatment 
in the absence of a clear evidence base thus limiting health care expenditure and re-
imbursement. This situation became increasingly unsatisfactory to patients, as well as 
health care purchasers and providers; subsequently NICE experienced pressure to 
reconsider initial guidance in the light of a growing body of evidence demonstrating the 
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clinical and cost effectiveness of VV interventions, especially non-surgical endovenous 
techniques. Correspondingly, the revised evidence-based NICE Guidance (CG168) of July 
2013 147 advised that symptomatic CEAP class C2 patients be referred for specialist 
clinical and duplex ultrasound assessment with treatment allocated according to an 
interventional treatment hierarchy (endothermal ablation, foam sclerotherapy or surgery) in 
preference to conservative therapy with compression hosiery 18. NICE CG168 and the 
accompanying Quality Standards (QS) for commissioning 148 have been widely welcomed 
by patients and endorsed by professional bodes such as the Vascular Society of Great 
Britain and Ireland (VSGBI) and the Royal College of Surgeons (RCS) 149. Increasing 
pressure on NHS resources and PMIs means that the publication of national guidelines 
such as NICE CG168 does not always lead to changes in commissioning, referral practice 
and reimbursement. The aim of this study, therefore, was to evaluate the impact of CG168 
on the referral and management of VV at the Heart of England NHS Foundation Trust 
(HEFT), which serves a population of about 1.2 million people in East Birmingham, UK. 
 
3.1.3    Methods 
A prospectively gathered database of all VV interventions (delivered by 6 consultant 
vascular surgeons who offered endovenous and surgical interventions (one consultant 
offered only surgical treatments referring people appropriate for endovenous interventions 
to the other consultants) performed at HEFT from 1 January 2012 (18 months before the 
publication of NICE CG168, group 1) to 31 December 2014 (18 months after publication, 
group 2) was supplied by the HEFT Performance Unit using Hospital Episode Statistics 
(HES) data. Electronic patient records were interrogated for Intervention type, CEAP 
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class/clinical grade at presentation and early (up to 6 weeks) complications.  The 
characteristics of group 1 and group 2 were compared using the χ2 test. Ethical committee 
approval was not sought for sections 3.1-3.3 as these sections formed part of service 
evaluation and utilised anonymised routinely collected healthcare data. Data on leg ulcer 
(sections 3.2 and 3.3) patients was also recorded as part of the screening logs for the 
EVRA trial. 
 
3.1.4    Results 
During the three-year study period 670 patients (738 legs) underwent either conventional 
surgery (CS), endothermal ablation (ETA) by radio-frequency ablation (RFA) or 
ultrasound-guided foam sclerotherapy (UGFS). A significantly greater number of people 
were treated earlier in the course of venous disease in CEAP class 2/3 (53% group 1 and 
65.2% group 2, p=0.0022, χ2) in the period after publication of CG 168 guidance (Table 
3.1.1). 
 
Publication of CG168 was also associated with a subsequent 65% (p=0.0001, χ2), increase 
in the number of patients undergoing interventions for VV in group one, 253 patients (48% 
men, mean age 54, range 20-91, SD15) and group two, 417 patients (46% male, mean age 
54, range 14-60, SD15). Figure 3.1.1 demonstrates a steepening of the curve after July 
2013, implying an increasing number of patients were undergoing VV treatments. This is 
confirmed by Figure 3.1.2, showing a greater number of patients treated per month 
comparing the Jan 2012 to June 2013 periods with the subsequent 18 months.  CG168 was 
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associated with a significant reduction in the use of surgery (131 patients [52%] group 1 vs. 
127 patients [30%] group 2, p=0.0003, χ2).  There was no change in the use of 
endothermal ablation (30 patients [12%] group 1 vs. 45 patients [11%] group 2) but a 
significant increase in ultrasound guided foam sclerotherapy occurred  (92 patients [36%] 
group 1 and 245 patients [59%] group 2, p=0.0001, χ2). The numbers of patients in each 
treatment category are shown in Table 3.1.2.  
 
Figure 3.1.1. Cumulative Number of Patients Treated by Date 
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Figure 3.1.2. Number of Patients Treated per Month 
 
 
Table 3.1.1. CEAP Clinical Grade in Group 1 and 2 Before and After Publication of 
CG168 
Group 1 Group 2 
CEAP Number Percentage CEAP Number Percentage 
C2 94 37.2% C2 231 55.4% 
C3 40 15.8% C3 41 9.8% 
C4 80 31.6% C4 99 23.7% 
C5 18 7.1% C5 19 4.5% 
C6 21 8.3% C6 27 6.5% 
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Up to and including, 6-week follow up, five complications were noted in the CS cohort, 
seven complications were noted in the conventional surgery cohort, in groups 1 and 2 
respectively and none with ETA (Table 3.1.2). One complication occurred in the group 2 
UGFS cohort (unplanned accident and emergency attendance with a small area of phlebitis 
requiring reassurance and simple analgesia). No endovenous complications were noted for 
group 1. Group 2 included 1 death (after conventional surgery) from pulmonary embolus 
(Table 3.1.2). 
Table 3.1.2.    6-Week Complications After VV Treatments 
Group 1 Group 2 
Surgery 
(n=131) 
ETA (n=30) 
UGFS 
(n=102) 
Surgery (n=127) 
ETA 
(n=45) 
UGFS (n=245) 
Wound 
infection 2 
none none 
Wound infection 
3 
none Phlebitis requiring 
unplanned hospital 
visit 1 Calf vein 
DVT 1 
  DVT 1  
Seroma 1   Seroma 1   
Post 
procedural 
ulcer 1 
  Hyperaesthesia 1   
   
Thigh haematoma 
1 
  
   Death 1 (PE)   
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3.1.5    Discussion 
The present study clearly indicates that publication of the NICE CG168 and the 
accompanying QS for commissioning, supported by guidance from the VSGBI, the RCS, 
and the Venous Forum of the Royal Society of Medicine 150, has led to a marked and 
precipitate increase in the numbers of patients referred, undergoing specialist assessment 
and intervention for VV at HEFT. An increase was detectable just before July 2013(Fig. 
3.1.2), perhaps as a result of the increased awareness of varicose vein treatments from 
launching the new guidelines locally to community practitioners. The guidance was 
notified via letters to general practices, at community practice study days for doctors and 
community nurses and “informationals” in local press. Furthermore, in line with NICE 
recommendations, patients are being referred at an earlier stage (CEAP class 2 and 3, 
Table 3.1.1) and are more likely to undergo endovenous rather than surgical treatment as 
shown by the changes in numbers of patients treated in each treatment category (Table 
3.1.2). As comprehensively reviewed in CG168, there is a large evidence base 
demonstrating that non-surgical, interventions for CEAP C2-C6 VV, especially, are highly 
clinically 151 and financially effective 152, 153. Only 5-7% of VV patients present with 
thrombophlebitis, bleeding, skin changes or ulceration 154, 155 and so previous guidelines 
had excluded many people with symptomatic VV from highly effective treatment that is 
associated with a marked improvement in health related quality of life; such treatment is 
extremely safe and well tolerated as shown by the low complication rate in the HEFT 
series (Table 3.1.2). Endovenous treatment allows a rapid return to normal activities 
representing excellent ‘value for money’ for the NHS 156-158. Furthermore, conservative 
management does not appear to prevent progression to worse CEAP class venous disease 
159, 160 and a systematic review could not demonstrate that compression hosiery alone was 
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adequate to slow progression or prevent recurrence 161. The use of compression stockings 
is well known to have poor compliance and despite their use, surgical treatment of VVs 
has been demonstrated to result in a greater improvement to quality of life and symptoms 
151, 152 than stockings alone. A large increase was seen in UGFS treatments (Table 3.1.2) 
and the vascular surgery department at HEFT has published extensively on UGFS 
outcomes 69, 162-164 there being little difference in patient reported outcomes when 
comparing ETA to UGFS 165. HEFT is able to offer UGFS at a fraction of the cost of ETA 
and this was a likely factor contributing to the increased use of this endovenous treatment 
modality.  
 
Limitations 
Data was collected through interrogation of prospectively gathered data. NICE CG168 was 
advertised locally to GPs by letters and at vascular themed community teaching days. 
During the study period the authors are not aware of any significant changes to the study 
population or to the number of referrers and the author can see no indication that the 
patient population served by HEFT would have changed significantly during the study 
period. This population however, is highly multi-culturally and socio-economically 
diverse166 and may not be representative of the United Kingdom as a whole. The waiting 
lists across adjacent hospital trusts may have influenced patients to chose HEFT over other 
trusts through the ‘choose and book system;’ however, the author was unable to obtain 
accurate waiting list times for the study period from all surrounding NHS trusts to evaluate 
any bias this may have caused. HEFT vascular department is also known to have an 
interest in venous disease, which may have influenced referring practitioners. 
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3.1.6     Conclusion 
Updated NICE guidelines and quality statements have greatly improved access to, and 
delivery of, evidence-based VV treatment in the HEFT catchment area. Continued 
advertisement of new guidelines and their recommendations to referrers will ensure that 
these improvements will be sustained in the longer term.  
 
3.2   IMPACT OF UK NICE CLINICAL GUIDELINE 168 ON REFERRALS TO A 
SECONDARY CARE BASED LEG ULCER SERVICE 
 
CG168 recommended that all those with varicose veins and a skin break below the knee 
present for two weeks or longer should be referred for specialist vascular opinion. Data 
presented in this section was collected in an attempt to assess the impact of this 
recommendation on referral numbers to a local (HEFT) secondary care vascular service.  
3.2.1    Abstract 
 
• Background: Leg ulcers are a common cause of morbidity and disability and result 
in significant health and social care expenditure. NICE Clinical Guideline (CG) 
168 sought to improve care of patients with leg ulcers, recommending that patients 
with a break in the skin below the knee that had not healed within 2 weeks be 
referred to a specialist vascular service for diagnosis and management. 
 
• Aim: To determine the impact of CG168 on referrals to a leg ulcer service. 
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• Methods: Numbers of patients referred with leg ulceration during the 18-month 
period prior to CG168 (January 2012-June 2013) and the 18-month period 
commencing 6 months after CG 168 publication (January 2014-June 2015) were 
compared.    
 
• Results: There was a 2-fold increase in referrals (181 patients, 220 legs vs. 385 
patients, 453 legs) but no change in mean age, gender or median-duration of ulcer 
at referral (16.6 vs. 16.2weeks). The mean time from referral to specialist 
appointment increased (4.8 vs. 6weeks, p=0.0001), as did the number of legs with 
superficial venous insufficiency (SVI) (36% vs. 44%, p=0.05). There was a trend 
towards more SVI endovenous interventions (32% vs. 39%, p=0.271) with an 
increase in endothermal procedures (2 vs. 32 legs, p=0.001) but no change in 
sclerotherapy treatments (24 vs. 51 legs). In both groups 62% legs had compression 
hosiery. There was a reduction in numbers of legs treated conservatively with 
simple dressings (26% vs. 15%, p=0.0006). 
 
• Conclusion: Since CG168 there has been a considerable increase in leg ulcer 
referrals; however, patients are still not referred until ulceration has been present 
for many months. Although many ulcers are multi-factorial and the mainstay of 
treatment remains compression; there has been an increasing trend toward 
endovenous intervention in SVI. Further efforts are required to persuade 
community practitioners to refer patients earlier, to increase awareness in patients 
and to encourage further investment in chronically underfunded leg ulcer services. 
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3.2.2    Introduction 
In the UK leg ulcers are estimated to affect 1% of the adult population with a greater 
preponderance (3-5%) in people aged over 65 167. Leg ulcers are associated with a 
significant reduction in quality of life for affected individuals 168, 169 and their families and 
carers 170 as well as considerable health and social care expenditure. Most leg ulcers are 
vascular in aetiology 171 and it is widely accepted that a prompt and full specialist 
assessment of the underlying venous and/or arterial disease is required in order to 
maximise chance of healing and to minimise recurrence rates 172. In recognition of this, the 
NICE Clinical Guideline (CG) 168 recommended that all people with a break in the skin 
below the knee that has not healed within 2 weeks be referred to a specialist vascular 
service 173. The aim of the study described in this section was to determine the impact of 
UK NICE CG 168 on referrals to the specialist leg ulcer service of the University of 
Birmingham academic department of vascular surgery at HEFT. 
 
3.2.3    Methods 
Patients referred to the University of Birmingham academic vascular unit specialist leg 
ulcer clinic based at Solihull Hospital, part of the Heart of England NHS Foundation Trust 
(HEFT), during an 18 month period prior to CG 168 (January 2012 to June 2013) were 
compared with those referred during an 18 month period commencing 6 months after   
publication of CG 168 (January 2014 to June 2015). HEFT covers a catchment population 
of approximately 1.2 million people comprising a mixture of inner city, socially deprived 
patients along with those from affluent suburbs. Referrals to the service were accepted 
from all sources, the vast majority came from general practitioners and community nurses. 
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All patients were assessed for vascular disease with presence of pulses and/or ankle 
brachial pressure index (ABPI) for arterial disease and for deep and superficial venous 
insufficiency with duplex ultrasonography. Data was gathered through retrospective 
interrogation of routinely collected NHS data and a prospective database of all patients 
referred with a leg ulcer. Venous disease was defined as the presence of superficial and/or 
deep venous incompetence (SVI/DVI) exceeding >0.5s on duplex ultrasonography. 
Significant arterial disease was defined by an ABPI of less than 0.8 at rest. The 
characteristics of the two groups of patients were compared using t-test and χ2-test as 
appropriate using the analysis programme SPSS 22 (IBM, USA). 
 
3.2.4    Results 
After publication of CG 168 there was an approximately 2-fold increase in referrals (181 
patients, 220 legs vs. 385 patients, 453 legs) but no change in age (mean, range, 
respectively: 75, 23-98 vs. 76, 33-104, years), gender (47% vs. 43% male) or median or 
inter-quartile range (IQR) duration of ulcer history at referral (respectively, 16.6, 7-30 vs. 
16.2, 6-46, weeks) or at first clinic appointment (respectively 20, 12-36 vs. 23, 12-52 
weeks) (Table 3.2.1).  A mean of 9.5 patients/month were referred before the CG 168 
guideline increasing to a mean of 17.5 patients/month with obviously, a corresponding 
increase in overall numbers of patient referrals after guideline introduction (Figure 3.2.1, 
Table 3.2.1). Mean time from referral to first clinic appointment increased (4.8 vs. 6 weeks, 
p = 0.0001) (Table 3.2.1), as did the proportion of legs with SVI (82 legs, 37% vs. 214 legs, 
47%, p = 0.05) (Table 3.2.2). There was no change in the proportion of legs with DVI 
(8.2%, 1 obstruction and 17 reflux vs. 8.8%, 11 obstruction and 29 reflux), traumatic / 
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pressure ulceration (22 legs, 10% vs. 37 legs, 8.2%), functional venous insufficiency 174 
(57 legs, 26% vs. 86 legs, 19%), or with pure arterial ulcers (21 legs, 9.5% vs. 53 legs, 
11.7%, Table 3.2.2). It is axiomatic that the exact numbers of patients in the various 
categories of venous disease would be greater in view of the overall approximately 2-fold 
increase in number of people referred (Table 3.2.1).  Significantly less legs with mixed 
arterio-venous ulcers (13 legs, 5.9% vs. 6 legs 1.3%, p = 0.0018) and proportionately less 
non-arterial, non-venous ulceration (106 legs, 48% vs. 154 legs, 34%, p=0.0012) were seen 
in the period after CG 168 publication  (Table 3.2.2). There was no significant increase in 
the proportion of legs with SVI undergoing superficial venous intervention (32% vs. 
39%)(Table 3.2.3).  No patient had traditional venous surgery. There was a significant 
increase in endothermal ablation procedures (2 vs. 32 legs, p = 0.001) but no statistically 
significant change in ultrasound-guided foam sclerotherapy although overall numbers of 
legs were greater (24 vs. 51 legs) (Table 3.2.3). Both groups of patients received 
compression hosiery in equal proportions (136 legs, 62% vs. 281 legs, 62%) but there was 
a significant reduction in legs treated conservatively with simple dressings only (52 legs, 
11.5% after publication of CG168, before CG168 corresponding figures were 26% vs. 58 
legs, 26%, p = 0.0006) (Table 3.2.3); clearly this represented a 15% decrease in the use of 
simple dressings after introduction of CG168. Arterial ulceration was treated using an 
endovascular approach in 21 legs (6 legs in group 1 and 15 legs in group 2) and by means 
of surgery in 10 legs (1 leg in group 1 and 9 legs in group 2) (Table 3.2.3). Some patients 
in groups 1 and 2 were diagnosed with ‘non-vascular’ causes of leg ulceration and these 
are detailed in Table 3.2.4. 
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Figure 3.2.1. Leg Ulcer Referrals by Month 
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Table 3.2.1 Patient Characteristics, Leg Ulcer History And Service Involvement 
 
Feature Before CG 168 (Group 1) After CG 168 (Group 2) 
Number referred 181 385 
Number of legs ulcerated 220 453 
Age   Mean 
          S.D. 
          Range 
75 
13.5 
23-98 
76 
12.7 
33-104 
Gender 
Male number (%) 
Female number (%) 
 
85(47) 
96(53) 
 
166(43) 
219(57) 
Ulcer duration (weeks) at 
referral  - median 
Interquartile range 
 
16.6 
7-30 
 
16.2 
6-46 
Ulcer duration at first 
appointment – median 
Interquartile range 
 
20 
12-36 
 
23 
12-52 
Patients referred per month  
            Mean 
            S.D. 
 
9.5 
3.0 
 
17.5 
9.5 
Time to first appointment 
(weeks) –  
            Mean 
            S.D. 
 
 
4.8 
2.5 
 
 
6* 
3.5 
 
*p<0.0001, χ2, all other features not statistically different though overall referral numbers 
clearly increased 
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Table 3.2.2   Aetiological Processes in Ulceration in Referred Patients 
 
Feature Before CG 168 
Group 1 
After CG 168 
Group 2 
SVI 
Number (%) 
 
82 (37) 
 
214 (47)* 
DVI (total) 
Number (%) 
 
18 (8.2) 
 
40 (8.8) 
DVI with obstruction 
(number) 
 
1 
 
11 
DVI with reflux (number) 17 29 
Trauma/pressure 
ulceration: number (%) 
22 (10) 37(8.2) 
Functional Venous 
Insufficiency 
57 (26) 86 (19) 
Pure Arterial Ulcers 
numbers (%) 
 
21 (9.5) 
 
53 (11.7) 
Mixed Arterio-venous 
Ulcers – Number (%) 
 
13.5 (5.9) 
 
6 (1.3)** 
Non-arterial, Non-venous 
Ulcers Number (%) 
 
106 (48) 
 
154 (34)*** 
 
Numbers in features column denote number of legs seen in referred patients.  * p<0.05, **  
p<0.0018, ***p<0.0012 (all p values for χ2 comparing group 1 with group  2 patients 
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Table 3.2.3   Treatments for Ulceration in Referred Patients 
Method 
Before CG 168 
Group 1 
After CG 168 
Group 2 
Simple dressings number (%) 58 (26.4) 52 (11.5)** 
Compression hosiery number (%) 136 (62) 281 (62%) 
Intervention for SVI number (%) 70 (32) 177 (39) 
Endothermal ablation number (%) 2 (0.9) 32 (7.1)* 
UGFS 24 (10.9) 51 (11.3) 
Endovascular treatment for arterial ulcer number (%) 6 (2.7) 15 (3.3) 
Figures relate to number of legs with ulceration (total 220, 453 in groups 1 and 2 respectively). * p 
=0.001 or ** 0.0006,  χ2 comparing groups 1 and 2 
 
 
Table 3.2.4 Non-Vascular Causes Of Leg Ulceration in Referred Patients  
Ulceration Cause 
Legs (group 1) 
(n=220) 
Legs (group 2) 
(n=453) 
Rheumatoid arthritis 4 1 
Lymphoedema 6 7 
Oedema with congestive cardiac failure 3 2 
Diabetic foot ulcer (neuropathy) 2 7 
Allergy to ointment 0 1 
Elephantiasis verruca nostra 0 1 
Infected orthopaedic prosthesis 0 1 
Pyoderma gangrenosum 4 1 
Warfarin skin necrosis 1 0 
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3.2.5    Discussion 
Perhaps unsurprisingly, there is strong evidence that early diagnosis and treatment of leg 
ulcers improves healing and reduces recurrence rates resulting in less health and social care 
expenditure 172, 175, 176. CG168 recommends that people with a below the knee break in the 
skin which has not healed within 2 weeks are referred for specialist vascular assessment. It 
is anachronistic therefore, that the NICE clinical knowledge summary 177 published in 
2015 (which appears to be based on earlier advice from the Scottish Intercollegiate 
Guidelines Network (2010) 178 and Royal College of Nursing guidance (2006) 179) 
recommend referral only when 12 weeks of community management has not resulted in 
improvement or healing? Perhaps this inconsistency helps, at least in part, to explain why, 
in spite of an approximate doubling of referrals to the HEFT specialist leg ulcer clinic, 
over half of referred patients had their ulcer for more than 16 weeks at the time of referral 
with no improvement in the history of ulcer duration ascertained at the times of referral or 
clinic first appointment before or after CG168 (Table 3.2.1)? Although no information is 
available on those people who were not referred, bearing in mind the catchment size of 
approximately 1.2 million, there seems no reason to suspect significant changes in the 
study population or referral sources over the period of interest. Features of the patient 
groups 1 and 2 ‘before and after NICE CG168’, respectively were similar in terms of 
demographics, ulcer history and the frequency of the use of simple dressings and 
compression hosiery (Tables 3.2.1 and 3.2.3); this suggests stability of patient 
characteristics from the ‘pre-CG 168’ through the ‘post- CG168’ study periods and similar 
practice in sources of referral. In further support of this contention, is the absence of 
substantial differences in the aetiological processes involved in the leg ulcers seen in 
patient groups 1 and 2, although there was a 10% increase in the numbers of legs with 
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superficial venous insufficiency, there were lesser numbers of mixed, arterio-venous and 
proportionately fewer non-arterial, non-venous ulcers in group 2 (Table 3.2.2). The 
mixture of inner city deprived areas and affluent suburbs forming the HEFT vascular 
service catchment makes it likely that there remains a significant, but unknown group of 
patients with leg ulcers who have never been referred for specialist assessment. 
Extrapolating Mekkes’ prevalence of 1% 167, gives an estimated prevalence of 12 000 
patients suffering ulceration in HEFT’s catchment area. An increase in referrals after 
CG168 introduction was clearly shown (Table 3.2.1, Fig. 3.2.1); however, whilst the latter 
portion of the curve in Fig. 3.2.1 appears to show a ‘tailing off ‘of referrals, this may well 
result from the increased waiting time from referral to specialist review (Time to First 
Appointment in Table 3.2.1) plus the limited service personnel numbers?  
 
Current data further emphasise the importance of engaging with colleagues in primary care, 
as well as affected individuals and their families/carers 180 so that all are aware of the 
strong evidence to show that prompt referral for specialist assessment improves healing 
and reduces recurrence rates and decreases overall expenditure on health and social 
services 181, 182.  Future work could concentrate on closer working between secondary care 
vascular services and community practitioners and encouraging general practices to audit 
their leg ulcer patient referrals to ensure all appropriate patients receive secondary care 
assessment on a timely basis. Despite no increase in clinic space or staffing the 
approximate doubling of referrals led to only a one week increase in time to first clinic 
appointment (Table 3.2.1) without increase in clinic space or staffing. The HEFT leg ulcer 
clinic personnel comprise mainly research doctors and nurses who are not funded by the 
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NHS. It is interesting to consider that if this were not the case, perhaps a significant 
increase in waiting time for specialist opinion would have developed, and NHS waiting -
time targets would have been breached 183 so highlighting the need for additional resources 
particularly as awareness of guidelines and correspondingly early referral numbers has 
continued to grow.  
 
As expected, although most ulcers were predominantly vascular in aetiology, many were 
multi-factorial in origin (Tables 3.2.2 and 3.2.4). There was a significant increase (37 to 
47%) in the proportion of legs with SVI (Table 3.2.2) and in the proportion of legs with 
SVI that had been ulcerated for less than 6 months. This may relate to the local promotion 
of the NIHR HTA-funded  “Early Endovenous Reflux Ablation (EVRA)” Trial increasing 
the local awareness of SVI as a cause for leg ulceration among community practitioners in 
addition to increased awareness of potentially treatable venous disease in leg ulceration 
after publication of CG168. Comparison of the figures in Table 3.2.2 with other ulcer 
series 171, 184, 185 suggests the proportion of ulcers caused by “pure” SVI may be falling; 
additionally a lower proportion of DVI ulceration in group 1 and 2 (Table 3.2.2) was 
encountered than described in other studies 186. The previous literature may have 
overestimated the occurrence of DVI ulceration as venous ulcer experts attract more 
complex disease or population differences may have played a role? Specifically, 
significant numbers of patients were referred with functional venous insufficiency (FVI) 
(Table 3.2.2) defined as the presence of skin changes (lipodermatosclerosis, haemosiderin 
deposition, healed or active ulceration) but without demonstrable superficial and/or deep 
venous disease on duplex ultrasonography 174. Factors contributing to the presumed 
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ambulatory venous hypertension and impaired calf muscle pump dysfunction include 
sedentary lifestyle, cardio/respiratory disease, working in a standing position, and 
especially, morbid obesity (Section 2.2, Obesity and Chronic Venous Insufficiency 
Disease). 
 
Compression remains a mainstay of venous leg ulcer management 187 (either compression 
hosiery or bandaging are equally appropriate 188); this treatment was used to a similar 
extent in both ‘pre-CG 168’ and ‘post-CG 168’ patient groups (Table 3.2.3) and is 
applicable not only to SVI ulcers (whether intervention is offered or not), but also to those 
with DVI and FVI 189, 190. There is a general view in vascular surgical departments that 
there is a reluctance to apply adequate compression in primary care as a result of concern 
about potentially undiagnosed arterial disease and difficulty with patient compliance. 
There is always a consideration that a significant minority of ulcers are not ‘vascular’ and 
it is particularly important that a malignant aetiology is not missed 191.  
 
NICE CG 168 recognises that the management of leg ulcers requires a multi-disciplinary 
approach co-ordinated by the vascular specialist. Patients with venous and/or arterial 
disease need careful assessment and investigation to plan appropriate interventions and 
where possible, for conservative management, close co-operation with multi-disciplinary 
colleagues, e.g., in areas of dermatology / anaesthetics / pharmacy / palliative / community 
care. The ‘open-door’ policy of the HEFT clinic was a catalytic factor in the markedly 
increased referral rate shown in Fig.3.2.1 and Table 3.2.1 and this situation ensured that the 
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people with leg ulcers of ‘non-vascular’ causation listed in Table 3.2.4, received prompt 
specialist diagnosis and referral to appropriate specialties/multi-disciplinary care.  
 
Differing leg ulcer care models, e.g., via dermatologists, phlebologists or wound care 
centres, exist throughout Europe. The salient points remain similar for each model, the 
emphasis being upon early specialist assessment/diagnosis and working with the patient to 
plan an appropriate treatment strategy. Whichever model is utilised depending upon local 
healthcare resources and protocols, this must be the cornerstone of effective leg ulcer 
management to maximise healing rates 192? An interesting sequel to the current thesis 
might be a study to evaluate any change in these treatment models in response to NICE 
Guidance CG 168? 
 
Limitations 
Data was collected through interrogation of prospectively gathered data. NICE CG168 was 
advertised locally to GPs by letters and at vascular themed community teaching days. The 
author is not aware of any significant changes to the study population or to the number of 
referrers (either general practitioners or community nurses) to the leg ulcer clinic during 
the study period. Through careful planning the waiting times were only marginally 
increased compared to pre-CG168. Patients and primary care practitioners may have 
referred more patients to HEFT through the ‘choose and book’ system preferentially. There 
may have been increased referrals if community practitioners were aware of the EVRA 
trial, which initiated recruitment in October 2013 and that HEFT vascular department has 
an interest in venous disease research. As described in section 3.1, the catchment area 
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served by HEFT is highly multi-culturally and ethnically diverse and may not be truly 
representative of the UK as a whole. 
 
3.2.6    Conclusion 
NICE Guidance CG 168 was associated with an approximately two-fold increase in 
referrals of people with leg ulcers to the HEFT academic vascular unit leg ulcer service. 
The dramatic increase in new patient numbers resulted in a lengthening of the waiting time 
for first clinic appointment of only just over one week in spite of the lack of extra clinic 
space and minimal personnel numbers. Unfortunately there was no decrease in the duration 
of leg ulcer history such that there remains a need to reinforce the message of CG 168 to 
make early referral for leg ulcers to obtain a specialist vascular opinion by working more 
closely with community practitioners and encouraging patients to seek early medical 
attention in the presence of leg ulceration. It may help to amalgamate different guideline 
resources such as the NICE guidelines and clinical knowledge summary to clarify the 
situation for community practitioner colleagues. 
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3.3 IMPACT OF NICE CLINICAL GUIDELINE 168 AND SOCIAL 
DEPRIVATION ON ACCESS TO INTERVENTIONAL TREATMENT FOR 
SYMPTOMATIC VARICOSE VEIN AND SPECIALIST REFERRAL FOR 
LEG ULCERATION AT A LOCAL, EAST BIRMINGHAM LEVEL 
 
By increasing the access to a hierarchy of VV treatments it is important that CG168 does 
not disadvantage those from less privileged areas, this is particularly important for leg 
ulceration. Leg ulcers (LU) are associated with increased socio-economic disadvantage and 
therefore secondary care must ensure it makes services as accessible as possible. The 
research for this section attempted to examine any effect of CG 168 on access to secondary 
care management of VV and LU for people with social deprivation before and after CG168. 
 
3.3.1    Abstract 
 
• Background: NICE clinical guideline CG 168 aimed to improve the 
management of lower limb venous disease by innovatively recommending 
interventional treatment for all people affected by symptomatic varicose veins 
(VV) and specialist vascular referral for all people suffering from a leg ulcer 
(LU) that had been present for >2 weeks.  
• Methods: The study aimed to utilise Index of Multiple Deprivation quintiles 
(IMD-Q) as a measure of social deprivation to assess the impact of CG168 on 
interventional treatment for symptomatic VV and LU referrals in the highly 
multi-cultural, socio-economically diverse, mixed urban/suburban population of 
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approximately 1.2 million people living in and around East Birmingham, UK. 
IMD-Q were used to compare levels of social deprivation of people undergoing 
interventions for symptomatic VV or referred with a LU during 18-month 
periods before and after publication of CG168. The referring general 
practitioner practices (GPP) were also recorded. 
 
• Results: There was no change in overall IMD-Q distribution before and after 
CG168 in terms of VV interventions; however, there was a non-significant 
increase in the proportion of people classified in the IMD-Q5 quintile 
representative of the greatest level of social deprivation. After CG168, fewer 
IMD-Q5 people with LU were referred, with a shift in referrals towards those 
from less socially deprived areas. More GPP referred people with both VV and 
LU after CG168 and those that referred patients before and after CG168 tended 
to refer more after introduction of CG168. 
 
• Conclusions:  CG168 has increased VV interventions as well as the number 
referred with LU but this improvement in access to treatment and referral may 
have disproportionately favoured the more socio-economically privileged. 
Professional and public awareness is required to ensure the beneficial impact of 
the CG168 recommendations are maximised and that those with the greatest 
health needs have equal access to evidence-based management of their venous 
disease. 
 
•  
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3.3.2     Introduction 
The NICE clinical guideline, CG 168 of July 2013, aimed to improve the management of 
lower limb venous disease innovatively recommending interventional treatment for all 
people affected by symptomatic varicose veins (VV) and specialist vascular referral for all 
people suffering from a leg ulcer (LU) that had been present for 2 or more weeks 173. 
Although little is known about the effects of social deprivation on the epidemiology of 
uncomplicated VV, there is considerable evidence of an association between LU, often the 
most severe manifestation of lower limb venous disease and social deprivation 193.  
 
The index of multiple deprivation (IMD) methodology, based on a UK government 
qualitative study of deprived areas within England 194, assigns each postal code an overall 
deprivation score based upon seven domains: income, employment, health deprivation and 
disability, education and skills and training, barriers to housing and services, crime and 
living environment. These scores are then divided into quintiles (Q) with Q1 indicating the 
least and Q5 the most deprived. 
 
The aim of this study was to examine the impact of CG 168 and social deprivation on 
access to interventional treatment for symptomatic VV and specialist vascular referral for 
LU using the CEAP classification system [18] (Section 1.1.5 and Table 1.1.5.1) to estimate 
the grade of venous disease severity and Index of Multiple Deprivation quintiles in people 
referred before and after the introduction of CG 168. A particular focus was whether 
publication of CG 168 had increased access to care at The Heart of England NHS 
Foundation Trust hospitals for people from more socially deprived areas of East 
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Birmingham where a greater need for such services might be anticipated. The Heart of 
England NHS Foundation Trust (HEFT) comprises three hospitals and serves a highly 
multi-cultural, socio-economically diverse, mixed urban and suburban population of 
approximately 1.2 million people living in and around East Birmingham, UK.  
 
3.3.3    Methods 
Patients (n = 1236) undergoing surgical or endovenous intervention at the Heart of 
England NHS Foundation Trust (HEFT) for symptomatic VV, or referred because of LU, 
during 18 month periods before (1 January 2012 to 30 June 2013, group 1) and after (for 
VV, from 1 July 2013 to 31 December 2014; for LU, from 1 January 2014 to 30 June 
2015) publication of CG 168 were compared in terms of clinical severity (CEAP clinical 
grade) 18, index of multiple deprivation quintile (IMD-Q) and the referring General 
Practitioner Practice (GPP). 
 
3.3.4    Results 
• VV Interventions Before And After Publication Of CG 168 
Publication of CG 168 was associated with a 65% increase in the number of people 
(253 to 417) undergoing intervention for symptomatic VV at HEFT. This increase 
was observed in all IMD-Q and there was no significant change in the IMD-Q 
distribution overall (Table 3.3.1) or, specifically, in those undergoing surgery, 
endothermal ablation, or ultrasound guided foam sclerotherapy. Inspection of the 
raw data in Table 3.3.1 shows greater numbers of people in IMD-Q 5 than in the 
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other quintiles were referred before and after CG 168, though this was not 
statistically significant. There was an overall increase in patients undergoing 
intervention for CEAP clinical grade (C) 2 and 3 disease but no significant 
association between this increase and the distribution of IMD-Q between the two 
groups. There was also no significant change in the IMD-Q of people undergoing 
intervention for CEAP C4 and C5 disease. A non-significant increase (from 29 to 
52 % of total) in the number of IMD-Q5 (most deprived) people undergoing 
intervention for CEAP C6 disease was seen (Table 3.3.2).  
 
Table 3.3.1    VV Interventions Before and After CG 168 by IMD-Q 
 
Before CG 168 After CG 168 
 
IMD Quintile Patients (n) % Patients (n) % p-value 
1 49 19.4 75 18.0 0.731 
2 54 21.3 76 18.2 0.374 
3 48 19.0 69 16.5 0.486 
4 25 9.9 56 13.4 0.214 
5 77 30.4 141 33.8 0.412 
Total 253 100 417 100 0.529 
 
P values for χ2 Tests 
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Table 3.3.2 VV Interventions Before and After CG 168 in Patients With Open LU  
(CEAP C6) 
 
 
Before CG 168 After CG 168 
 
IMD Quintile Patients (n) % Patients (n) % p-value 
1 5 23.8 3 11.1 0.435 
2 2 9.5 5 18.5 0.643 
3 4 19.0 4 14.8 0.696 
4 4 19.0 1 3.7 0.211 
5 6 28.6 14 51.9 0.184 
Total 21 100 27 100 0.190 
 
LU referrals before and after publication of CG 168 
 
Publication of CG 168 was associated with a 112% increase in the number of people (181 
to 385) referred with LU. Although an increase was observed in all IMD-Q there was a 
significant (χ2, p = 0.023) change in the IMD-Q distribution away from the most socially 
deprived quintiles with the proportion of IMD-Q5 referrals falling from 30% to 20% (χ2, p 
= 0.011) after CG 168 (Table 3.3.3). With the exception of functional venous insufficiency, 
defined as typical venous skin changes and ulceration in the absence of superficial or deep 
venous reflux on duplex ultrasound and which was most commonly seen in IMD-Q5 
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patients in both cohorts, there was no significant relationship between LU aetiology and 
IMD-Q either before or after publication of CG 168. 
 
Table 3.3.3   LU Referrals Before and After CG 168 by IMD-Q 
 
Before CG 168 After CG 168 
 
IMD Quintile Patients (n) % Patients (n) % p-value 
1 37 13.2 94 24.4 0.348 
2 43 23.8 84 21.8 0.684 
3 20 11.0 74 19.2 0.021 
4 26 14.4 55 14.3 0.961 
5 55 30.4 78 20.3 0.011 
Total 181 100 385 100 0.023 
 
People undergoing VV intervention before and after publication of CG 168 had been 
referred from 102 and 122 GPP respectively (Table 3.3.4). After CG 168 patients came 
from 44 ‘new’ GPP that had not referred people prior to introduction of CG 168. In 
contrast 22 GPP that had referred people prior to CG 168 did not refer any people 
afterwards whilst of the 78 GPP represented in both cohorts, 45 referred more people in the 
post-CG 168 cohort, 19 made the same number and 14 sent fewer referrals.  
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Table 3.3.4   East Birmingham GP Practice Referrals For VV Intervention Before/After 
CG168 
Number Before CG 168 After CG 168 
Total Patients Referred 181 385 
Total GPP referring 102 122  
Additional GPP (‘new’) only 
referring after CG 168 
- 44 
GPP not referring after CG 
168 
- 22 
GPP referring before and after 
CG 168 
78 78 
After CG168* GPP patient 
referrals number more  
Unchanged 
Less 
- 
 
- 
- 
45  
 
19  
14  
GPP = General Practitioner Practices 
 
Following publication of CG 168, the number of GPP referring people with LU increased 
from 64 to 102 with 54 ‘new’ GPP referring people after CG 168, but, 16 GPP from which 
referrals had been made before CG 168 did not refer any people after CG 168 (Table 3.3.5). 
Of the 48 GPP referring LU’s before and after CG 168, 48% referred more patients after 
CG168, 29% referred the same number of patients, and 23% referred fewer patients. 
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Table 3.3.5 East Birmingham GP Practice Referrals For Leg Ulcer Before and After CG 
168 
Number Before CG 168 After 168 
Total 181 385 
Total GPP referring 64 102 
Additional ‘New’ GPP referring 
ONLY after CG 168 
- 54 
GPP not referring after CG 168 - 16 
GPP referring before and after CG 
168 
48 48 
After CG 168 GPP 
Patient referral number/percentage 
More 
Unchanged 
Less 
 
 
 
 
 
 
23 (48%) 
14 (29%) 
11 (23%) 
  TOTAL 48 
 
 
3.3.5    Discussion 
• VV interventions 
In a literature search examining the relationship between social deprivation and the 
prevalence and management of uncomplicated VV, only the Edinburgh vein study was 
seen to have looked at deprivation (social class was determined by occupation) and 
found no relationship 2. The study in this section demonstrated that although 
publication of CG 168 led to an increase in the overall number of VV interventions, it 
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was not found to have produced any significant difference in the IMD-Q distribution 
of the people being treated (Table 3.3.1). Thus, people from the most deprived quintile 
(IMD-Q5) accounted for approximately 30% of VV interventions before and after CG 
168.  
 
In relation to CEAP clinical grade, publication of CG 168 was not associated with any 
detectable change in the IMD-Q distribution except with regard to C6 disease where 
there was a decrease in IMD-Q1 and an increase in IMD-Q5 (Table 3.3.2) but this 
trend did not attain statistical significance. Perhaps overall low patient numbers were 
responsible for the absence of statistical significance since the percentage change was 
relatively substantial. It would have been hoped that that CG 168 might have improved 
access to superficial venous intervention in CEAP grade 6 disease (VV with open LU) 
for the most socially deprived.  There was no relationship between IMD-Q and choice 
of superficial venous treatment with most patients being treated with endovenous, non-
surgical techniques in both cohorts and across all IMD-Q groups (Tables 3.3.2 and 
3.3.3). 
 
• LU Referrals 
Although publication of CG 168 was associated with a considerable increase in the 
overall numbers of people with LU being referred from all IMD-Q, the number of 
people from IMD-Q5 decreased proportionally and significantly from about 30% to 
about 20% of total referrals (p=0.011, χ2, Table 3.3.3). This could suggest that people 
from socially deprived areas of East Birmingham may have been less likely to be 
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referred than those from more affluent areas; although, as noted above, once referred, 
they appear to be just as likely to receive intervention? The reasons for this apparent 
lack of access to LU referral among the most socially deprived people remain unclear. 
People from socially deprived areas are more likely to have significant co-morbidity 
such as diabetes 195, atherosclerosis 196, as well as higher levels of cigarette smoking 
197 and obesity 195, all of which are recognised risk factors for LU development, poor 
ulcer healing and higher recurrence rates. It may be, however, that despite a greater 
LU burden 198, people from socially deprived backgrounds are less likely to present to 
medical services in a timely manner 199. It is also possible that GPP in more socially 
deprived areas are relatively underfunded 200 and so less likely to make specialist 
referrals? By contrast, more affluent and perhaps better-educated patients may be more 
health aware and so more likely to seek medical advice earlier and then request 
specialist referral for their health problems. In Table 3.3.2, the raw data showed and 
increase of IMD-Q5 patients after CG168 who underwent VV interventions for open 
LU though this was not statistically significant at P=0.184 using χ2 testing (Table 
3.3.2). This trend might be interpreted as supporting the argument regarding late 
presentation of patients in IMD-Q5 with health problems in general and leg ulceration 
in particular. Non-parametric statistical tests such as χ2are generally regarded as less 
sensitive than parametric methods and so the test may have ‘missed’ significance; 
however it seems possible that the trend was due to chance and the numbers of patients 
were relatively small for the IMD-Q5 group in CEAP C6 grade being, respectively, 6 
and 14 before and after CG168. The observation, although only a ‘trend,’ is at odds 
with the ‘statistically significant’ p value  = 0.011 (χ2) for a decrease in the overall 
numbers of people in IMD-Q5 referred for LU after CG168 (Table 3.3.3). The latter 
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finding although statistically significant, may not be clinically significant in the ‘real 
world’ since the numbers of people referred in IMD-Q5 increased from, respectively, 
55 to 78 comparing ‘before’ and ‘after’ CG168? The explanation may simply be that 
more people in the other categories of IMD-Q were referred in greater numbers by 
chance? 
 
§ General Practitioner Practice (GPP) Referral Patterns 
Encouragingly, publication of CG 168 was associated with an overall increase in the 
number of GPP referring people for intervention for symptomatic VV and for LU 
(Tables 3.3.4 and 3.3.5). Furthermore, the majority of practices that referred people 
before and after CG168 referred more people afterwards for both referral indications. 
A few GPP referred fewer or no VV and LU people after CG168; however, these 
tended to be smaller GPP that referred one or two patients before the guideline was 
published. Unfortunately, it is not possible to accurately calculate the IMD-Q 
distribution for patients from individual GPP as the catchment areas are often complex 
with imprecise boundaries; hence the decision to study patients by their individual 
post-code of residence and not by registered GPP. It was a general impression that the 
GPP that referred more patients with VV and LU after CG168 tended to be located in 
the more affluent regions of the HEFT catchment area. This, if it were possible to 
quantitate, would further strengthen the suggestion that publication of CG 168, whilst 
improving access to care for lower limb venous disease overall, may have tended to 
favour those who reside in the less socially deprived areas of East Birmingham? 
 
 
 
 
85 
NICE clinical guidelines are highly respected in the UK and overseas. Although the 
recommendations contained in guidance are advisory and have no legal authority in 
terms of the services that individual NHS clinical commissioning groups (CCGs) 
choose to purchase and prioritise, it would be unwise for CCG and individual GPP to 
ignore or contravene them. Thus in other areas, such as the management of the ‘diabetic 
foot’, a failure to follow NICE guidelines may be accepted as a breach of duty in cases 
of alleged clinical negligence 201. There appears to be no reason why this should not be 
the case in respect of CG 168; however, colleagues in primary care often claim, 
justifiably, that they are overwhelmed by guidelines and that it is simply impossible to 
be aware of and follow them all, all of the time. 
 
§ Limitations 
Clearly patients must present to medical services to receive a diagnosis of VV/LU. The 
greater likelihood of less socially deprived people to seek medical attention may 
disproportionately increase the numbers with VV/LU giving a false impression of greater 
incidence/prevalence in these groups. A more likely explanation is the lesser tendency for 
socially deprived people to present to medical services with, correspondingly, an under-
estimate of numbers of VV/LU. IMD-Q scores cannot distinguish between these 
alternative explanations of the data. Those from more socially privileged background are 
also more likely to seek private medical attention and this may further skew the 
proportions of people in different IMD-Q groups presenting with VV and LU. The area 
served by HEFT is highly multi-culturally and ethnically diverse166 and may not be truly 
representative of the UK as a whole (as described in section 3.1) and the data are based on 
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postal code and not on the true socioeconomic standing of individuals, e.g., those who are 
deprived but live in affluent areas; both these features may be confounding factors in the 
interpretation of the results of this study. It was decided not to include analysis by ethnicity 
from local data as this was extremely poorly recorded (significant numbers had absence of 
recorded ethnicity and ethnicity recorded very broadly e.g. Asian, white, black). The 
catchment population is predominantly white European and south Asian (Indian, Pakistani, 
Bangladeshi etc.)166.Within the significant proportion of south Asians in HEFT’s 
catchment, there is considerable variation and heterogeneity. Although the heterogeneity of 
south Asian populations has not been investigated in VV/LU, there is evidence to suggest 
significant effect in other disease states202, 203  
 
§ Future Directions 
At present little is known about the incidence of VV or indeed LU related to social 
deprivation in the general population, as patients are required to present to medical 
services to obtain a diagnosis, although LU has a higher proportion of socially deprived 
patients seeking medical attention 193 and is likely to be more common in these groups. It 
may be possible for large observational studies (such as the Edinburgh Vein Study) to 
estimate this from re-analysis of their data. This work would be important to ensure social 
demographics are considered in strategies to ensure equality of access to services. 
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3.3.6    Conclusion 
It is very encouraging that, at least in the HEFT catchment area, CG 168 has clearly 
increased numbers of interventional treatments for VV as well as the number of people 
being referred with LU. There is a possibility depending upon result interpretation, that this 
improvement in the care of lower limb venous disease may have disproportionately 
favoured people from more privileged socio-economic backgrounds. Further professional 
and public awareness may help to ensure that the beneficial impact of the CG 168 
recommendations is maximised and that those with the greatest health needs have equal 
access to evidence-based management of their lower limb venous disease. 
 
3.4     ANALYSIS OF THE EFFECT OF NICE CLINICAL GUIDELINE 168 ON 
GENERAL PRACTICE MANAGEMENT AND REFERRAL OF VARICOSE 
VEINS AT NATIONAL LEVEL USING THE HEALTH IMPROVEMENT 
NETWORK DATABASE 
 
General Practitioner (GP) colleagues have a major role to play in community management 
of superficial venous disease and in the referral of patients to specialist, secondary care 
vascular surgery services. This section aimed to study the effect of NICE CG 168 on 
management of VV   by GP Practices at a national level as a sequel to the study of local 
GP management in East Birmingham as described in Section 3.3 above. In view of the 
recognition of aspects of social deprivation in venous disease, the latter feature was studied 
as for the East Birmingham cohorts in Section 3.3, but this time using the Townsend 
Quintile method 204 to represent social deprivation (as this is the method used to record 
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deprivation within the health improvement network database) instead of the Index of 
Multiple Deprivation Quintiles or IMD-Q which was the method chosen for local 
deprivation measurement. 
 
Comparison of Townsend Quintiles Versus Index of Multiple Deprivation 
Townsend quintiles were used in the analysis of sections 3.4 and 3.5, compared with IMD 
used in 3.3. Townsend quintiles consist of 4 domains (of equal weighting), compared to the 
7 domains in IMD (with unequal weighting) (Table 3.4.1). Townsend data focuses on a 
narrow definition of material deprivation. This allows consistent calculation over time in 
comparison to IMD, which reviews and revises its indicators for each domain at each 
update and therefore does not allow direct comparison between different IMD datasets. 
Townsend data is based upon UK census data, which is infrequently (2001, 2011, 2021) 
updated in comparison to IMD, which is updated more frequently (2007, 2010, 2015, 
2019) and may lead to bias. However there appears to be good correlation between 
Townsend and IMD in urban areas, certainly in terms of health205. The correlation is less 
marked in rural areas, perhaps a weakness of Townsend, where significant weight is placed 
on car ownership which, is more of a necessity in areas of poor public transport206. There is 
also greater heterogeneity in the rural population which may mask some areas of poverty207. 
Both however are excellent at recording deprivation and allowing the calculation of 
deprivation over small areas. Whilst the direct comparison of IMD data and Townsend 
data cannot be made, the comparison of general trends is possible205.  
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3.4.1    Abstract 
• Background: National Institute for Health and Care Excellence (NICE) Clinical 
Guideline (CG) 168 (July 2013) recommended all patients with symptomatic 
varicose veins (VV) be referred for consideration of intervention. Additional 
advice was to no longer prescribe compression hosiery with the contention that 
conservative management was no longer appropriate unless intervention was 
contraindicated. Primary care functions as ‘gatekeeper’ to vascular services in the 
NHS and the awareness of this new guidance was critical to ensure patients were 
managed in line with national, contemporary, evidence-based recommendations. 
 
• Aim: To assess the impact of NICE CG168 on primary care management of VV at 
a national level. 
 
• Methods: Interrogation of 18-month periods before and after NICE CG168 
introduction using the Health Improvement Network (THIN) database was used to 
analyse VV diagnosis, referral patterns, to secondary care, compression hosiery 
prescriptions and interventions recorded in primary care. 
 
• Results: 18-month cohorts (of approximately 2 million patients) before and after 
CG168 were well matched demographically and of these, 13 014 patients were 
diagnosed with VV before CG168 and 12 466 ‘post-CG168’. An increase in 
referrals from 3 173 to 3 457 was noted with a Cox model hazard ratio post-CG168 
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of 1.15 (p<0.001). A decrease in compression hosiery prescription (Cox hazard 
ratio 0.93, p=0.008) and an increase in VV interventions (Cox hazard ratio 1.16, 
p=0.023) were also apparent after CG168. 
 
• Conclusion: There was a statistically significant change in the management of VV 
in primary care in line with recommendations of NICE CG168. This response to 
CG168 requires continued involvement of GP and other community practitioner 
colleagues to ensure its maintenance and to further the improvement in the 
management of superficial venous insufficiency. 
 
 
3.4.2    Introduction 
General practitioners (GPs) in the UK function as ‘gatekeepers’ in the process of referral 
of patients to hospital specialists. These community - based colleagues are required to have 
broad knowledge of patient care and management and to refer appropriately to ensure 
efficient and effective secondary care in the UK. To aid accurate and appropriate referrals 
to hospital specialists, as well as guide investigation and management in secondary care, 
the National Institute for Health and Care Excellence (NICE), produce clinical guidelines 
(CG). These at the time of writing, number one hundred and seventy-two, cover a broad 
spectrum of topics and are accompanied in addition by other advisory documents, e.g., 
clinical knowledge summaries. It is therefore difficult for GP colleagues to maintain 
awareness of all up to date guidance, whilst managing a continually increasing work load 
which leaves little time for other professional and non-clinical duties 208, 209.  
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Using The Health Improvement Network (THIN) database, the effects on referral to 
vascular specialists and primary care management of NICE CG168 were studied. The 
changes that CG168 recommended in primary care were that all people with symptomatic 
varicose veins (VVs) should be referred for specialist opinion; previously only those with 
skin changes, ulceration or bleeding could be referred for funded intervention; furthermore, 
compression hosiery was no longer seen as adequate treatment for simple superficial 
venous reflux unless intervention was inappropriate, e.g., during pregnancy 21. With the 
prevalence of VVs between 20-50% 3, 14, it is likely that a large number of patients will 
present to GPs complaining of symptomatic VVs; therefore primary care awareness of 
CG168 is paramount in ensuring NICE guidelines are followed and patients have equality 
of access to superficial venous interventions. 
 
The THIN database comprises approximately 450 GP practices with data for over 3.5 
million ‘current’ patients; data is entered at a GP practice level and is wholly anonymous 
for use in healthcare research. The database is representative of the UK national population 
for demographics and major disease prevalence 210. 
 
3.4.3    Methods 
• Study Design And Setting  
A retrospective open cohort study was undertaken using The Health Information 
Network database (THIN) into which UK general practices using the Vision patient 
record system, enter anonymous patient electronic medical records 
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(www.inps.co.uk/vision/health-improvement-network-thin). THIN includes patient 
records from approximately 3 million current and 12 million former patients (4.5% of 
UK population), and may be generalised to the UK population 210.  
Data in THIN include patient demography, coded symptoms and diagnoses, clinical 
measurements, prescriptions and laboratory test results. Data collection for this was 
approved by the National Health Service (NHS), Southeast, Multicentre Research 
Ethics Committee in 2003, with prior approval for individual studies using anonymous 
data subject to review by an independent scientific review committee. 
(http://csdmruk.cegedim.com/our-data/ethics.shtml). This study, pertaining to sections 3.4 
and 3.5, was approved by a THIN Scientific Review Committee (16THIN007) 
(Appendix 2). The Townsend Quintile system was used as a measure of social 
deprivation in the population studied 204. 
 
• Study Periods 
NICE CG168 was introduced in July 2013.  The pre-CG168 period for the study was 
defined as 1/1/2012 – 30/6/2013 and the post-CG168 period was defined as 1/1/2014 – 
30/6/2015. A six-month interval directly after the introduction of the guidelines was 
included before the ‘post-CG168’ to allow for them to be fully disseminated.  
 
• Practices and Participants  
Individual practices were included from the latest of: Vision installation date plus one 
year (to ensure that they were using the system to its full extent); practice acceptable 
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mortality recording date (to ensure accurate recording of patient deaths and de-
registrations) 211; and the start of the period of interest. Practices could continue to 
contribute patients to each cohort until the earlier of the following time intervals: end 
of the period of interest and last data collection from practice. Practices outside 
England and Wales and practices that did not contribute patients for the entire study 
period (1/1/2014 - 30/6/2015) were excluded. 
 
Individual practice patients were eligible from inclusion from the latest of the 
following time intervals: practice start date; one year after registration with practice (to 
allow baseline data to be collected by the practice) and age 18 years. Patients exited 
from the cohort at the earliest of the following time intervals: practice end date; patient 
death and patient deregistration. Patients who were temporarily registered and patients 
with inconsistent registration dates were excluded.  
 
• Case And Outcome Definitions 
The index date for a new episode of varicose veins was defined as the date of a Read 
code (http://systems.digital.nhs.uk/data/uktc/readcodes, Appendix 3) for varicose veins 
in a patient record if there was no record of varicose veins in the previous year.  A 
referral for an index varicose vein episode was defined as a referral flag in the patient 
record on the same day as the index episode, or a Read coded entry indicating an 
outward referral within one day of the index episode. Referrals during follow-up were 
identified using the same method if the patient had a subsequent GP consultation for 
varicose veins. Compression stocking use after the index episodes and within each 
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period was identified from prescribing data, and varicose vain surgery was identified 
using Read coded records for the procedures of interest. The most recent BMI recorded 
prior to each index episode was used in the analyses.  
• Analysis 
The baseline demographic and clinical characteristics of the source population and 
varicose vein cases for the two periods of interest were obtained. χ2 tests were used to 
compare data and Wilcoxon rank-sum tests were used to compare non-normally 
distributed continuous data. Separate Cox proportional hazard models were used to 
compare the risk of referral and surgery adjusted for patient demographic and clinical 
characteristics. Multiple imputation (10 imputations) was used to allow individuals 
with missing BMI, Townsend quintile, and urban/rural residence data to be included in 
the analyses 212.  Model standard errors were adjusted for clustering by practice and 
non-linear effects for age and BMI on each outcome using fractional polynomials 213. 
All analyses were carried out using Stata 14.2 (StataCorp 2015, Stata Statistical 
Software, College Station, Tx). 
 
• Validation of THIN Data Extraction 
No previous work using the THIN database and VV has been published, however there 
have been numerous validation studies performed in other areas, e.g., leg ulceration 
(allowing validation of section 3.5)214, pharmaco-epidemiological research215, non-
melanoma skin cancer216, death and sucide217. Unfortunately there was not time during 
the researching and writing of this thesis to perform a validation exercise and the lack 
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of linking to HES data at present prevented this from being used to validate VV data. 
The data extraction methods described above have been well described and to ensure 
accurate data retrieval from the THIN database, with such wide-ranging validation for 
disease states, the author makes the assumption that the THIN data for VV is of 
reasonable quality to allow its analysis and inclusion in this thesis but accepts that if 
patients present with two diagnoses (e.g. chest pain and varicose veins), there may be 
poorer recording of what might be considered more medically ‘trivial’ diagnoses. 
 
3.4.4    Results 
Two hundred and eighty five practices with approximately 2 million patients were eligible 
for inclusion within the study and both pre and post-CG168 groups of patients, diagnosed 
with new or recurrent VV, were well matched for number of patients, age, sex, Townsend 
quintile as a measure of social deprivation, urban/rural residence and ethnicity (Table 
3.4.1). The two ‘pre-CG168’ and ‘post-CG168’ cohorts numbered 13014 and 12466 
patients, respectively.  
 
There was an increase in the number of patients referred to vascular surgery after CG 168 
introduction: 3173 patients, pre-CG168) (24% of the pre-CG168 eligible population) to 
3457 patients, post-CG168), (28% of the post-CG168 eligible population). Patients were 
15% more likely to be referred post-CG168 (Hazard ratio, HR=1.15; 95% CI 1.09-1.20; 
p<0.001). Most of these patients were referred immediately after their initial consultation 
(Figure 3.4.1); median interval between VV consultation and referral was 1.5 days in both 
pre and post-CG168 groups. A reduction occurred in the number of patients prescribed 
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compression hosiery from 2558 (20%) pre-CG168, to 2292 (18%) post-CG168 and 
patients were 7% less likely to receive compression stocking prescription post CG-168 
(HR=0.93; 95% CI 0.88-0.98; p=0.008). The majority of patients were prescribed 
stockings within the first few days of their initial consultation (Figure 3.4.2). There was 
also an increase in the number undergoing superficial venous intervention (possible 
techniques were, conventional surgery, endothermal ablation or ultrasound-guided foam 
sclerotherapy) from 469 (3.6%) patients pre-CG168 to 526 (4.2%) patients post-CG168 
with the post-CG168 figure reflecting a 16% increased chance of undergoing VV 
intervention (HR=1.16; 95% CI 1.02-1.31; p=0.023) which was, specifically, statistically 
significant for endothermal ablation post-CG168 (Table 3.4.2). There was no difference 
between both cohorts in median time between GP consultation for VV and timing of VV 
intervention at 4.13 months pre-CG168 and 4.35 months post-CG168.  
 
Cox models for VV referral were constructed (Table 3.4.3). Age, through a non-linear 
relationship (Figure 3.4.3) was a statistically significant factor, the chance of referral with 
varicose veins being highest between late 30s and 60 years of age. Males were 5% less 
likely to be referred (HR=0.95 relative to females; 95% CI 0.91-1.00; p=0.05). Those from 
Townsend quintiles 3, 4 and 5 were less likely to be referred than those from quintiles 1 
and 2 (Table 3.4.3). BMI (although statistically significant, the hazard ratio was 0.99) or 
urban residence did not seem to have a significant impact on referral for VV to secondary 
care although the number of people referred seemed to fall off at higher BMI values (Fig.  
3.4.5). 
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For VV intervention, Cox models were constructed (Table 3.4.4). The relationship with 
age and VV intervention was non-linear (Figure 3.4.4), demonstrating increased likelihood 
of intervention from late 30s to 60 years of age. BMI, as mentioned above, was also related 
(again non-linearly) those with a BMI of >30kg/m2 (Figure 3.4.5) being less likely to 
receive VV intervention. Townsend quintiles 3, 4 and 5 were less likely to receive VV 
intervention compared to those in Quintile 1 (Table 3.4.4). Urban residence compared with 
rural location did not have an effect on the chance of intervention (Table 3.4.4) even 
though the raw data in Table 3.4.1 showed approximately four-fold greater numbers for 
urban relative to rural location. 
 
3.4.5    Discussion 
It is encouraging that after the introduction of NICE CG168 there was a statistically 
significant increase in VV referrals at a national level demonstrated by the numbers from 
the THIN Database (Table 3.4.3). This finding may be interpreted as a sign of increased 
awareness of these guidelines and their recommendations for primary care physicians. The 
hazard ratio for the increase in referrals of 1.15(CI 1.1-1.2, p<0.001, Table 3.4.3) is 
slightly below the predicted increase of 25% by the NICE CG168 costing report 47, the 
latter, however, also included the predicted increase in leg ulcer referrals. The lack of a 
striking difference in numbers of patients presenting with primary or recurrent VV before 
and after guidelines (Table 3.4.1) suggested that more work was needed to further engage 
public awareness to continue improved utilisation of health care resources. As expected 
most patients were referred immediately after their initial consultation in line with NICE 
CG168 recommendations that conservative management is not appropriate (Fig. 3.4.1). 
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The effects of CG168 were also noted in prescription of compression hosiery. After 
CG168, rates of prescription reduced, although not as much as anticipated; prescription of 
hosiery was made very rapidly, within the first few days for most patients (Fig.3.4.2) given 
how strongly guidelines recommend that treatment solely with compression hosiery was 
ineffective (unless intervention is contraindicated). Further encouragement of GP 
colleagues is needed in this area to reduce stocking prescription costs. Anachronistically, 
some attempts at patient education may limit attendance at GP practices for consultation 
for VV, despite the recommendations of CG168: the NHS choices website (last reviewed 
in September 2014) informs patients that they may be recommended 6 months of ‘self-
caring’ including compression stockings 218! This advice was reviewed in September 2016, 
but was sadly not amended in light of CG168 – it seems important that all sources of 
information from the NHS, particularly those based on national guidance should be 
harmonised to maximise impact and reduce confusion?  
 
Comparison of Townsend quintiles of social deprivation showed that the distribution of 
VV by Townsend quintile was equivalent to the distribution among the general population. 
There was some reduction in chance of referral for higher (more deprived) Townsend 
quintiles; however, the hazard ratios demonstrated this reduction was small in spite of the 
statistically significant p values (Table 3.4.4). This hopefully, implied reasonable equality 
of access to secondary care referral for those suffering from symptomatic VVs, although 
more work is needed to ensure access for all social groups for specialist opinions regarding 
their VV.  Work in coronary heart disease has demonstrated interaction between age and 
sex with social deprivation in terms of chest pain and coronary heart disease diagnoses219. 
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This study included the analysis of nearly 200 000 patients.  The potential for interaction 
between age, sex and deprivation with regards to varicose vein diagnoses and subsequent 
referral was not studied in this work due to considerably lower numbers and the time 
required to complete these analyses.  Epidemiological studies have suggested that VV are 
more commonly reported in women (see section 1.1.2).  However, thus far, the evidence 
that younger women from less socially deprived quintiles tend to be the most prevalent 
group seeking referral for their VV remains anecdotal. 
 
Numbers of VV interventions increased after CG168, appropriately, as it is recommended 
that all those with CEAP 18 clinical grade 2 VV or worse should be treated (Table 3.4.3). 
This increase was similar to the increase in proportion of referrals and again a similar 
amount below the increase predicted by NICE 47. Also it is encouraging that despite the 
increase in VV interventions, the time from referral to intervention did not increase (Fig. 
3.4.1), perhaps due to careful planning by secondary care vascular units in light of the 
publication of NICE CG168? The total numbers of patients undergoing treatment, however, 
were considerably lower than anticipated. It is possible that these rates are falsely low, as 
GP practices may not accurately record hospital interventions within their databases. A 
crude comparison was performed using the THIN database and NHS England hospital 
episode statistics (HES), suggesting that VV intervention rates were recorded as 
approximately 2 per 10 000 patients in the THIN database and 8 per 10 000 patients using 
NHS England HES procedure codes! As with other THIN database work, where the 
outcome of interest is under-reported 220, it can be assumed that the recording patterns of 
this data are likely to be broadly similar between the two cohorts and that the statistical 
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increase post-CG168 is clinically significant, particularly as the increase was equivalent to 
the increase in VV referrals. Unfortunately, at the time of writing linked data between 
THIN and HES is not available. Lack of experience in coding HES data at a primary care 
level and likely poor understanding of differing VV intervention types by non-clinical 
administrative staff, may explain the lack of marked changes in VV interventions. CG168 
recommended a treatment hierarchy of  
1. Endothermal ablation,  
2. Ultrasound-guided foam sclerotherapy  
3. Conventional surgery.  
In spite of the increase in endothermal ablation after CG168 (an increase of 47 procedures, 
p=0.025 for ‘post’ versus ‘pre -CG 168’, Table 3.4.2), the majority of VV interventions 
were recorded as conventional surgery. Coding errors are widely reported and can lead to 
significant loss of organisational income 221, 222, closer physician involvement can improve 
the accuracy of recording 223. It was also disappointing to note a lower likelihood of 
receiving VV interventions with increasing degrees of social deprivation (Tables 3.4.1 and 
3.4.3). This might, perhaps, be a product of patient unwillingness to undergo intervention 
once they have been reassured by specialist opinion that their problem is ‘solely varicose 
veins’ or alternatively, reluctance on the part of clinicians to treat what is likely to be a 
more co-morbid patient group who are possibly more likely to experience complications. 
The difference seems more likely to be co-morbidity based as suggested by the lower 
likelihood of treatment for those who are older and obese that was seen in the Cox model 
for VV interventions and indicated by Figures 3.4.4 and 3.4.5, respectively and Table 3.4.3. 
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Unfortunately, from THIN data the cause for the smaller number of treatments for more 
socially deprived patients cannot be determined. 
 
Limitations 
THIN database analysis may inflict bias in several ways.  There may be selection bias 
recruiting more ‘academically’ minded GP practices or those that benefit from the small 
pecuniary incentive from participating in THIN; therefore, there may be under-
representation from practices in deprived areas.  Data was collected through interrogation 
of prospectively gathered data on general practice electronic patient records (Vision 
software). Whilst patients were only entered into the analysis if GPs had been registered 
with THIN for more than 1 year with acceptable mortality rates etc., it is possible that 
through user error VV diagnoses were under-coded, for example, the instance of patients 
presenting with symptoms suspicious of another, more urgent condition such as 
malignancy may result in VV coding being overlooked as GPs only record events they 
deem relevant to patients’ care.  As described above, THIN data was not linked with HES 
at the time of analysis and this may have led to errors in recording VV interventions.  The 
use of multiple imputation to allow analysis of missing variables may have affected data 
evaluation as data is assumed to be missing at random. 
 
3.4.6    Conclusion 
The management and referral of VV patients has improved since the introduction of NICE 
CG168 in terms of increased referral and intervention and a reduction in prescription of 
compression hosiery. Further encouragement of GP colleagues and closer working 
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relationships between primary and secondary care is required to ensure the management of 
this extremely common health complaint continues to improve in line with NICE 
recommendations. Continuing efforts are needed to increase awareness of patients so 
empowering them to seek medical attention and referral for the management of their VV. 
 
Table 3.4.1 Comparison of Domains of Townsends vs IMD  
Townsend Domains IMD Domains 
Unemployment (25%) Income (22.5%) 
Overcrowding (25%) Employment (22.5)% 
Non-car ownership (25%) Education, skills and training (13.5) 
Non-home ownership (25%) Health/disability (13.5%) 
 Living environment (9.3%) 
 Barriers to housing (9.3%) 
 Crime (9.3) 
 
Figures in brackets – percentage contribution to overall score 
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Table 3.4.2: Characteristics of Incident Varicose Vein Patients 
 Pre-CG168 Post-CG168 p-value 
Number of Patients 13 014 12 466  
Male (%) 40.2 39.5 0.2840 
Mean age (SD) 62.7 (17.5) 61.8 (17.5) 0.7966 
Townsend Quintile (%)   0.108 
(Least deprived) 1 3 768 (29) 3 697 (30)  
2 2 981 (23) 2 808 (23)  
3 2 686 (21) 2 479 (20)  
4 2 102 (16) 2 079 (17)  
(Most deprived) 5 1 283 (10) 1 179 (10)  
Missing 194 (2) 224 (2)  
Urban/rural residence (%)   0.706 
Urban 10 358 (80) 9 865 (79)  
Rural 2 471 (19) 2 382 (19)  
Missing 185 (1) 219 (2)  
Ethnicity (%)    
Asian 260 (2.0) 264 (2.1)  
Black 83 (0.6) 89 (0.7)  
Chinese 21 (0.2) 20 (0.2)  
Mixed 29 (0.2) 31 (0.3)  
Other 66 (0.5) 65 (0.5)  
White 6 234 (47.9) 6 148 (49.3)  
Missing 6 321 (48.6) 5 849 (46.9)  
BMI: Mean (SD) 28 (6) 28 (6) 0.0520 
 
SD=standard deviation. χ2 used for count data, t-test for normally distributed continuous data. Wilcoxon 
rank-sum test used for non-normally distributed data   
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Table 3.4.3: Varicose Vein Interventions 
 Pre-CG168 Post-CG168 p-value 
Number of interventions (%) 469 (3.6) 526 (4.2) 0.023 
Intervention type   0.666 
Endothermal ablation 107 154 0.025 
Foam sclerotherapy 74 73 0.451 
Conventional Surgery 288 299 0.163 
 
 
 
Table 3.4.4: Cox Model for Varicose Vein Referral 
 Hazard Ratio 95% CI p-value 
Male 0.95 (0.91,1.00) 0.05 
Townsend    
(Least deprived) 1 (Reference) 1.00 - - 
2 0.99 (0.91,1.05) 0.513 
3 0.82 (0.76,0.89) <0.001 
4 0.90 (0.82,0.98) 0.016 
(Most deprived) 5 0.90 (0.81,1.01) 0.084 
BMI (per kg/m2) 0.99 (0.99,0.99) 0.002 
Urban residence 1.09 (0.98,1.22) 0.097 
Post-NICE CG168 1.15 (1.10,1.20) <0.001 
 
CI = confidence interval. Multiple imputation used for missing values of Townsend, BMI and 
urban residence. Standard errors adjusted for clustering by practice.  
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Table 3.4.5:  Cox Model for Varicose Vein Interventions 
 
 Hazard Ratio 95% CI p-value 
Male 0.87 (0.76,1.00) 0.058 
Townsend    
(Least deprived) 1 (Reference) 1.00 - - 
                           2 0.79 (0.65,0.97) 0.025 
                           3 0.70 (0.55,0.90) 0.005 
                           4 0.63 (0.48,0.82) 0.001 
(Most deprived) 5 0.49 (0.33,0.73) <0.001 
BMI_1 0.98 (0.98,0.99) <0.001 
Urban residence 0.99 (0.76,1.28) 0.923 
Post-NICE CG168 1.15 (0.99,1.32) 0.065 
 
CI = confidence interval. Multiple imputation used for missing values of Townsend, BMI and 
urban residence. Standard errors adjusted for clustering by practice. 
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Figure 3.4.1. Time to Varicose Vein Referral After Initial Consultation 
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Figure 3.4.2. Time to Prescription of Compression Hosiery After Initial GP Consultation 
 
 
Figure 3.4.3.  Effect of Age on Probability of Referral for Varicose Veins 
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Figure 3.4.4:  Effect of Age on Probability of Varicose Vein Intervention 
 
 
Figure 3.4.5.  Effect of BMI on Probability of Varicose Vein Intervention 
 
 
 
 
109 
3.5  ANALYSIS OF THE HEALTH IMPROVEMENT NETWORK DATABASE 
ON THE PRIMARY CARE MANAGEMENT OF LEG ULCERS AT A 
NATIONAL LEVEL  
 
NICE guidance CG 168 advocates referral to a vascular specialist of any leg ulcer lasting 
longer than two weeks; compliance with this recommendation should be taken as good 
clinical practice. Adherence to the advice to rapidly refer people with new diagnosis of 
leg ulceration was therefore explored at a national level as a sequel to the study of 
primary care leg ulcer management at a local level in East Birmingham as presented in 
Section 3.3. The methodology used for the current section was similar to that used in 
Chapter 3.4 above but has been described again, in detail, in the ‘Methods’ section 3.53 
below for the sake of clarity. 
 
3.5.1    Abstract 
• Background: NICE Clinical Guideline (CG) 168, published in July 2013 
predominates over other guidelines for management of leg ulcers (LU) in England 
and Wales; CG 168 recommends specialist referral for skin breaks below the knee 
that have been present for longer than 2 weeks.  
 
• Aim: To delineate the changes in primary care management of LU using a 
retrospective cohort study of prospectively gathered data from The Health 
Improvement Network database. 
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• Methods: Eighteen month periods before and after introduction of CG168 were 
examined analysing an eligible population of approximately 2 million adult 
patients. Those patients with a new diagnosis of LU in each time period were 
studied demographically and any related primary care coded episodes of referral 
for specialist review and superficial venous interventions were recorded. 
 
• Results: There were 7 532 new diagnoses of LU ‘pre-CG168’ and 7 462 ‘post-
CG168’. A lower proportion of male patients with LU were found (46.6% pre-
CG168, 46.9% post-CG168) in the eligible population. Patients with LU were 
older (median age both pre and post-CG168 cohorts of 77, pre-CG168 IQR 65-85, 
post-CG168 IQR 64-85)) than the eligible population; 2 259 (30.0%) patients were 
referred pre-CG168 and 2 329 (31.2%) were referred post-CG168 (slightly but not 
significantly more, p=0.053). A Cox model for leg ulcer referral computed a 
hazard ratio of 1.05 (95% CI 0.99, 1.11, p=0.096). There was an interval  (median) 
of 0.05 months between LU consultation and referral in both pre-CG 168 and post-
CG 168 cohorts with respective interquartile ranges of, pre-CG168, 0.05 to 0.20 
and post-CG168, 0.05 to 0.05. Patients were just as likely to receive superficial 
venous intervention (either surgery, endothermal ablation or ultrasound-guided 
foam sclerotherapy) in the pre-CG 168 as in the post-CG 168 periods; with a Cox 
model hazard ratio of 0.94 (95% CI 0.69, 1.27, post-CG168) and p=0.681 for post-
CG 168 relative to pre-CG 168.  
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• Conclusion: The apparent increase in the number of referrals for LU after CG 168 
did not reach statistical significance. Patients that were referred were sent to 
specialists early. Consolidation of LU guidance in the UK is required to further 
improve access to specialist opinion and referral should be open to all community 
practitioners. 
 
3.5.2    Introduction 
In the United Kingdom (UK), the Scottish Intercollegiate Network (SIGN) 178, the Royal 
College of Nursing (RCN) 179 and National Institute for Health and Care Excellence 
(NICE), in form of their clinical knowledge summary (CKS) 177 and Clinical Guideline 
(CG) 168 21, have all provided advice and recommendations for the management of leg 
ulcers (LU). Unfortunately, there are important inconsistencies revealed by comparison of 
these UK guidelines and by comparison with international guidelines 224 225. There is 
strong evidence to show that the longer a LU has been present, the larger it is likely to be, 
the longer it is likely to take to heal, the more likely it is to recur and the greater the 
resulting burden on health and social services. As such, there is widespread agreement 
among vascular specialists that early referral, leading to diagnosis and appropriate, 
evidence-based, treatment of LU results in more clinically successful and cost-effective 
care 172, 175 176 16 For this reason NICE CG168, which was published in 2013 and 
supersedes all other UK guidelines (outside Scotland) recommends that people with a ‘skin 
break, below the knee, which has not healed within 2 weeks’  be referred to a vascular 
specialist 21. The aim of the present study was to use The Health Improvement Network 
(THIN) database to determine whether publication of CG 168 had led to an increase in 
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compliance with the recommendations of CG 168 for the primary care management of 
people affected by LU at a national level as a sequel to the local, East Birmingham study 
described in Section 3.2.  
 
3.5.3   Methods 
§ Study Design and Setting  
A retrospective open cohort study was undertaken using The Health Information 
Network database (THIN), a large database of anonymous routine electronic 
medical records from approximately 450 UK general practices including patient 
records from approximately 3 million current and 12 million former patients 210 as 
described in Sections 3.4.3 and 3.4.4, above. Townsend Quintiles were used as an 
index of social deprivation in the study population as for Section 3.4, above. 
 
§ Study Periods 
NICE CG168 was introduced in July 2013.  The pre-CG168 period was defined as 
1/1/2012 – 30/6/2013 and the post-CG168 period was defined as 1/1/2014 – 
30/6/2015. A six-month gap directly after the introduction of the guidelines was 
included to allow for them to be fully disseminated.  
 
§ Practice and Participants  
Individual practices were included from the latest of: Vision installation date plus 
one year (to ensure that they were using the system to its full extent); practice 
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acceptable mortality recording date (to ensure accurate recording of patient deaths 
and de-registrations) 211; and the start of the period of interest. Practices could 
continue to contribute patients to each cohort until the earlier of the following 
dates: end of the period of interest and last data collection from the practice. 
Practices outside England and Wales, and practices that did not contribute patients 
for the entire study period (1/1/2014 - 30/6/2015) were excluded. 
 
Individual practice patients were eligible from inclusion from the latest of the 
following dates: practice start date; one year after registration with the practice (to 
allow baseline data to be collected by the practice); and age 18 years. Patients 
exited from the cohort at the earliest of the following dates: practice end date; 
patient death and patient de-registration. Patients who were temporarily registered 
and patients with inconsistent registration dates were excluded.  
 
§ Case and Outcome Definitions 
The index date for a new episode of leg ulcer was defined as the date of a Read 
code (http://systems.digital.nhs.uk/data/uktc/readcodes, Appendix 3) for leg ulcer 
in a patient record, if there was no record of leg ulcer in the previous year.  A 
referral for an index leg ulcer episode was defined as a referral flag in the patient 
record on the same day as the index episode, or a Read coded entry indicating an 
outward referral within one day of the index episode. Referrals during follow-up 
were identified in a similar manner if the patient had a subsequent GP consultation 
for leg ulcer. Leg ulcer surgery was identified using Read coded records for the 
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procedures of interest. The most recent BMI recorded prior to each index episode 
was used in the analyses.  
 
§ Analysis 
The baseline demographic and clinical characteristics of the source population and 
leg ulcer cases for the two periods of interest were described. χ2 tests were used to 
compare ‘count’ data, and Wilcoxon rank-sum tests were used to compare non-
normally distributed continuous data. Separate Cox proportional hazard models 
were used to compare the ‘risk’ or chance of referral and surgery and were adjusted 
for patient demographic and clinical characteristics. Multiple imputation (10 
imputations) was used to allow case histories with missing BMI, Townsend quintile, 
and urban/rural residence data to be included in the analyses 212. Model standard 
errors were adjusted for clustering by practice. Non-linear effects for age and BMI 
on each outcome were estimated using fractional polynomials186. All analyses were 
carried out using Stata 14.2 (StataCorp 2015, Stata Statistical Software, College 
Station, Tx). 
 
3.5.4    Results 
The two cohorts were well matched for age, sex, urban/rural residence, Townsend quintile 
and ethnicity. There were 7 532 new diagnoses of LU before and 7 462 after publication of 
CG168. Affected people were well matched for the above characteristics (Table 3.5.1). 
Compared with the eligible group as a whole, there were less men in the LU groups before 
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and after CG 168 as follows: pre-CG 168, 46.6% vs. 49.0% in the eligible population; 
post-CG168; 46.9% vs. 48.9% in the eligible population. LU patients were older than the 
general eligible population with median and inter-quartile age ranges, pre-CG 168, 77 [65-
86] vs. 48 [34-63] years and post-CG 168, 77 [64-85] vs. 48 [34-63] years for the total 
eligible population (Table 3.5.1). About 78% of LU patients in pre- and post-CG 168 
groups were of urban residence (Table 3.5.1). The raw data suggested that the number of 
people diagnosed with new LU decreased with the increasing Townsend Quintiles of social 
deprivation but proportionately there seemed no difference between pre- and post CG 168 
groups or between the LU groups and the total eligible population (Table 3.5.2). 
 
Cox model construction for LU referral (Table 3.5.3) demonstrated increasing age was not 
a significant factor (HR=1.00; 95% CI 0.99-1.00; p=0.001), the ‘statistically significant’ p 
value did not reflect clinical significance with the hazard ratio of 1 and narrow 95% CI; 
however, male sex increased likelihood of referral. More patients were of urban residence 
in both study groups as mentioned above  (Table 3.5.1) but the Cox proportional modelling 
for this feature did not demonstrate statistical significance (p=0.065, Table 3.5.3). Those 
from Townsend quintiles 3 and 4 were less likely to be referred than those from the least 
deprived Townsend quintile 1. 
 
Patients were just as likely to receive SVI intervention (surgery, endothermal ablation or 
ultrasound-guided foam sclerotherapy) post CG168. 87 patients underwent superficial 
venous intervention pre-CG168 and 80 post-CG168 with HR=0.94 (95% CI 0.69-1.27;  
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p=0.681).  A Cox model for leg ulcer intervention (for SVI) (Table 3.5.4) demonstrated a 
non-linear relationship with age, with increased hazard ratio of intervention for those aged 
from 50-70 years (Figure 3.5.2). There was also a 14% increase in intervention for males 
(HR=1.14; 95% CI 0.85-1.55; p=0.386), but this did not reach statistical significance. 
Townsend quintile did not appear to have an effect on the likelihood of undergoing SVI 
intervention. Those with BMI >30kg/m2 were less likely to undergo intervention (Figure 
3.5.3). There was no statistically significant difference in risk of intervention for SVI 
induced ulceration for rural versus urban residence.  LU incidence (new diagnoses per 
1000 patient years) was 28.64 (95% CI 26.44, 31.07) pre-CG168 and 27.85 (95% 
confidence interval (CI) 25.73, 30.20) and the adjusted incidence rate ratio pre-CG168 vs. 
post-CG168 was HR=0.97; 95% CI 0.94-1.00; p<0.001 (Table 3.5.5). 
 
Before CG 168, 2 259 (30.0%) people with a new diagnosis of LU referred pre-CG168 
compared with 2 329 (31.2%) after CG168 (p=0.053). Patients seemed 5% more likely to 
be referred after CG-168 (HR=1.05; 95% CI 0.99-1.11; p=0.096)(Table 3.5.5) but this was 
not statistically significant. There was a median (IQR) delay between consultation 
(diagnosis) and specialist referral of 0.05 (0.05-0.20) months before and 0.05 (0.05, 0.05) 
after CG 168 (Figure 3.5.1, Table 3.5.5); however, the interval between consultation and 
intervention increased from median 4.48 months (IQR 3.07, 7.47) pre-CG168 to 5.78 (IQR 
3.87, 10.74) post-CG168 (Table 3.5.5). 
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3.5.5    Discussion 
Disappointingly, this study suggests that publication of NICE CG 168 has led to no 
significant increase in primary care specialist referral rates for people newly diagnosed 
with LU; with around 70% of people with LU were not rapidly referred the small increase 
from 30% to 31.25% did not achieve statistical significance (p=0.053, Table 3.5.5). 
Certainly, the total number of referred patients did not differ significantly from pre- to 
post-CG 168 periods (Table 3.5.5) and the characteristics of the patient groups did not 
differ significantly on a clinical basis (Table 3.5.1, 3.5.3 and 3.5.5) or in terms of numbers 
eventually receiving interventional treatment for their superficial venous disease (Table 
3.5.4). Referrals are likely to be ‘under-coded’ and hopefully the true figure is a smaller 
departure from that recommended? Further reasons for the ‘static’ level of compliance 
might include ignorance of CG 168 or a preference to follow other guidelines. In stark 
contrast to NICE CG 168, the RCN, SIGN, and NICE CKS guidelines recommend referral 
only after 12 weeks of failed community management. The overall discouraging situation 
is however, mitigated by the observation that those people with a new diagnosis of LU 
who were referred, were referred almost immediately perhaps suggesting that where GP 
colleagues are aware of CG 168 they are willing to comply with its recommendation? 
 
A larger proportion of patients with greater degrees of social deprivation in Townsend 
quintiles 4 and 5 (and less in Townsend quintile 1) were diagnosed with LU compared with 
the eligible population (Tables 3.5.2, 3.5.3). This finding is similar to previous work which 
has shown an association of LU with increasing social deprivation 193. Evidence that social 
class inequality in access to healthcare has been shown in several studies 226 and it is quite 
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possible that the proportion of LU patients in Townsend quintiles 4 and 5 are actually 
under-represented and the disparity is actually far greater. At least there was no significant 
difference in the numbers of people receiving intervention for their superficial venous 
disease (Table 3.4.4). As previously demonstrated, LU was commoner in women and in 
the elderly (Tables 3.5.1, 3.5.3, 3.5.4, Fig. 3.5.2) 171 though interventions decreased with 
increasingly ‘older’ age (Fig. 3.5.2). It is possible this may be a product of elderly male 
reluctance to seek healthcare and the stigma of ‘seeking help’ 227. Seeking GP 
appointments later, led to poorer prognoses 228 and this reluctance may be the mechanism 
of the gender difference rather than a true reflection of higher incidence of LU in females? 
It is perhaps important for future LU guidance to specifically target elderly (in particular 
males) and the socially deprived to ensure adequate access to specialist review so 
improving healthcare seeking behaviour? This contention is supported by a reduced chance 
of referral for those from Townsend Quintiles 3 and 4 (but not from the most deprived 
quintile 5) (Table 3.5.3). Encouragingly however, as mentioned above, Townsend quintile 
did not seem to affect the likelihood of receiving an intervention for SVI induced 
ulceration (Table 3.5.4) perhaps reflecting the hoped-for equality of access to intervention 
in secondary care. 
 
Although urban versus rural residence did not affect likelihood of referral (Table 3.5.3) it 
seemed that proportionately there might have been a preponderance of LU in people from 
rural areas? Evidence has demonstrated that rural patients have significant barriers to 
healthcare including limited healthcare resources and difficulties in accessing transport 
(particularly important in LU patients who are often elderly) 229, 230. It is therefore 
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important to ensure rural patients continue to have access to specialist referral to ensure 
early review and that previously reported barriers do not prevent patient referral. 
 
CG168 is not specific to leg ulceration and indeed mainly covers guidance on management 
of varicose veins of the legs, however, the referral recommendations for LU patients are 
clear. It is not the only NICE guidance to have little impact upon patient management and 
indeed a study of the impact of NICE guidelines on GP prescribing patterns showed little 
was achieved 231. This may be a result of the sheer number of guidelines, most of which 
have recommendations with obvious implications for overworked general practitioners. 
NICE guidelines focused on specific specialties seem to have influenced practice more 
positively 232, 233, however this does not always seem to be the case 234, 235. Whilst slavish 
adherence to guidelines will not protect against litigation, their standards are often used as 
a benchmark for courts to judge clinical conduct 236 and although NICE guideline use in 
medico-legal cases has been limited thus far, it is likely to increase 201. It would seem 
therefore, that it is increasingly important that patients are cared for (whilst not necessarily 
appropriate for every patient) in close adherence to NICE recommendations. 
 
There was no change in superficial venous interventions for LU (Table 3.5.4) though 
overall numbers appeared low (~1% LU patients underwent intervention). Whilst the 
absolute numbers may be less important  (data in THIN database recorded from hospital 
based care episodes is currently not linked to Hospital Episode Statistics and is likely to be 
a considerable underestimate) the lack of increase may be a cause for concern? The effect 
of age on likelihood of SVI intervention interestingly, showed a reduced likelihood of 
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interventions for those <50 years, perhaps because non-SVI causes of ulceration are more 
likely in this age group and similarly, intervention ‘dropped off’ in those aged >70 years 
(Table 3.5.4, Fig. 3.5.2), perhaps as a result of a reluctance to intervene in a more frail and 
co-morbid group?  
 
Those people with a BMI >30 were less likely to receive SVI intervention (Tables 3.5.1, 
3.5.4, Fig.3.5.3).  This may be a result of immobility and co-morbid status, along with the 
likelihood of a more technically difficult procedure and higher risk of complications. 
Those who are obese however, are more likely to suffer ulceration 114 and are an 
increasingly prevalent group 237.  Certainly conventional surgery for venous insufficiency 
has been shown to reduce recurrence of venous ulceration 238 and with CG168 
recommending an endovenous first treatment strategy for varicose veins, this is supported 
by the early results of the Early Venous Reflux Ablation trial 
(www.nets.nihr.ac.uk/projects/hta/11129197). Hopefully longer-term follow-up will 
continue to add evidence to this field and may well result in an increase in beneficial 
interventions in the future?  
 
Limitations 
Methodology in 3.5 is similar to that of section 3.4 and therefore similar limitations apply 
to this section also. Perhaps, however, the diagnosis of a LU is seen as a more severe 
condition than ‘just’ VV and therefore is more likely to be recorded? Similarly, for section 
3.2, the recruitment for the EVRA trial may have influenced referrals although EVRA only 
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recruited patients from 20 centres in the UK and no significant increase in referrals was 
noted in the THIN data making this seem unlikely.  
 
3.5.6    Conclusion 
Leg ulceration tends to affect the elderly, female gender and more socially deprived. This 
section has shown that publication of CG 168 has not led to improved compliance with its 
advice on leg ulcer management in primary care at a national level. Therefore, leg ulcer 
management guidance in the UK requires consolidation to ensure clarity and consistency 
of message for all healthcare practitioners. Further efforts are required to publicise the 
importance of CG168 guidance to community health professional colleagues who refer 
patients to secondary care and amongst the socially deprived and elderly themselves.  
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Table 3.5.1: Characteristics of Incident Leg Ulcer Patients 
 
  Pre-CG168 Post-CG168 p-value 
No. Patients 7 532 7 462  
Male (%) 46.6 46.9 0.734 
Median age (IQR) 77 (65-85) 77 (64-85)  
Urban/rural residence (%)   0.029* 
Urban 5 784 (77) 5 825 (78)  
Rural 1 658 (22) 1 530 (21)  
Missing 90 (1) 107 (1)  
Ethnicity (%)   0.305 
Asian 66 (1) 66 (1)  
Black 54 (1) 72 (1)  
Chinese 4 (0) 1 (0)  
Mixed 8 (0) 10 (0)  
Other 13 (0) 16 (0)  
White 3 350 (45) 3 395 (46)   
Missing 4 037 (54) 3 902 (52)  
BMI: Mean (SD) 29 (8) 29 (8) 0.0234* 
 
SD=standard deviation. χ2 used for count data. *Wilcoxon rank-sum test used for non-
normally distributed data. Probability values relate to comparison of pre- with post-CG 
168 groups. 
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Table 3.5.2. Comparison Of Townsend Quintiles In The Eligible Population With The 
Population Having A New Diagnosis Of Leg Ulcer 
 
Townsend Quintile (%) Whole Cohort People Diagnosed With New LU 
Pre-CG168 Post-CG168 Pre-CG168 Post-CG168 
(Least deprived) 1 523 920 (27) 533 088 (27) 1 835 (24) 1 839 (25) 
2 419 856 (22) 427 415 (21) 1 639 (22) 1 638 (22) 
3 410 908 (21) 419 473 (21) 1 571 (21) 1 545 (21) 
4 345 372 (18) 362 651 (18) 1 449 (19) 1 454 (20) 
(Most deprived) 5 203 528 (10) 208 494 (10) 945 (13) 877 (12) 
Missing 39 842 (2) 49 002 (2) 93 (1) 109 (2) 
Total 1 952 426 2 000 123 7 532 7 462 
 
• % Refers to proportion of Townsend Quintiles in the pre- and post-CG 168 total 
eligible populations on the left, right hand columns refer to corresponding proportions 
in the leg ulcer groups 
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Table 3.5.3.  Cox Model for Leg Ulcer Referral 
 
 Hazard Ratio 95% CI P-value 
Total number of referrals Post –CG 168 1.05 (0.99, 1.11) 0.096 
Age  1.00  (0.99,1.00) 0.001 
Male 1.07 (1.01,1.12) 0.025 
Townsend Quintile    
(Least deprived) 1 (Reference) 1.00 - - 
2 0.93 (0.85,1.00) 0.055 
3 0.83 (0.76,0.92) <0.001 
4 0.87 (0.79,0.95) 0.003 
(Most deprived) 5 0.88 (0.78,1.00) 0.056 
BMI (per kg/m2) 1.00 (1.00,1.01) 0.075 
Urban Residence 1.15 (0.99,1.34) 0.065 
 
 
• Multiple imputation used for missing values of Townsend Quintiles, BMI and urban 
residence. Hazard ratio p values for significance of comparing pre- and post-CG 168 
groups. 
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Table 3.5.4.  Cox Model of Superficial Venous Intervention for Leg Ulceration 
 
 Hazard Ratio 95% CI P-
value 
Number of patients receiving all interventions 
Post –CG168 
0.94 (0.69, 
1.27) 
0.681 
Male 1.14 (0.85,1.55) 0.386 
Townsend    
(Least deprived) 1 (Reference) 
1.00 
- - 
2 0.84 (0.53,1.32) 0.446 
3 1.13 (0.71,1.80) 0.610 
4 0.74 (0.45,1.19) 0.216 
(Most deprived) 5 0.98 (0.53,1.78) 0.934 
BMI_1 0.99 (0.98,0.99) <0.001 
Urban Residence 1.12 (0.66,1.89) 0.673 
 
 
CI = confidence interval. Multiple imputations used for missing values of Townsend 
Quintiles, BMI and urban residence. Standard errors adjusted for clustering by practice. 
Hazard ratio p values are for the significance of comparing pre- with post-CG 168 groups. 
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Table 3.5.5 Occurrence And Referral Features For New Diagnosis Of Leg Ulcers 
 
 Pre -CG 168 Post- CG 168 
Number with new LU diagnosis 7532 7462 
Incidence of LU (new diagnosis per 1000 patient years) 
median and 95% CI 
28.6 (26.4, 
31.1) 
27.9 (25.7, 
30.2) 
Adjusted LU incidence rate ratio, 95% CI - HR 0.97 (0.94, 
1) 
p < 0.001 
Number of referrals of new LU (% of total LU patients) 2259 (30%) 2329 (31.2%) 
p = 0.053 
Likelihood of referral post – CG 168 (ratio and 95% CI) - HR 1.05 
(0.99, 1.11)  
p = 0.096 
Median (IQR) delay from new diagnosis to referral 0.05 (0.05-
0.2) 
0.05 (0.05-
0.05) 
Time/months to intervention* 4.48 (3.1-
7.5) 
5.78 (3.9-
10.8) 
 
*Time from new diagnosis to all interventions; all p values for comparison of pre- versus 
post-CG 168 
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Figure 3.5.1.   Time from LU Consultation to Referral to Specialist 
 
 
Figure 3.5.2.   Effect of Age on Probability of Superficial Venous Intervention for Leg 
Ulcer 
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Figure 3.5.3.   Effect of BMI on Probability of Superficial Venous Intervention for Leg 
Ulcer 
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Chapter 4 
DISCUSSION 
 
4.1   LIMITATIONS OF THESIS METHODOLOGY 
 
This thesis aimed to examine the impact of NICE CG168 on the referral and management 
of venous disease in both secondary care and primary care, at a local level in East 
Birmingham and at a national level via the Health Improvement Network database. Data 
for the studies were gathered in eighteen - month periods before and after the publication 
of guideline CG 168 in July 2013.   
 
Secondary care data from HEFT was a mixture of prospectively collected data and 
retrospectively analysed data from prospectively gathered databases. Data from secondary 
care was limited to the local trust catchment population of East Birmingham numbering 
1.2 million and comprising a mixture of inner city deprived and affluent suburbs and a 
wide-ranging ethnic diversity. The complexities and potential inaccuracies of data 
collected from hospital episode statistics (HES) generally prompted a decision to confine 
secondary care analysis to the carefully, prospectively collected information in the HEFT 
database. It was felt that inclusion of other units’ data would then, be less accurate as 
relying solely upon HES figures with no possible quality control checks. It was hoped to 
mitigate this potential source of error in the local, HEFT secondary care data by cross-
checking data entries against hospital operating logs and appointments using local 
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electronic clinical records to ensure the accuracy of the data and the inclusion of all index 
cases. All other data sources were compiled from prospectively kept data logs in the 
University of Birmingham Department of Vascular Surgery. These methods it was hoped, 
would reflect good clinical practice and provide reasonably accurate data so truly 
reflecting the effects of CG168.  
 
It is possible that the impact of NICE CG168 was exaggerated locally. This may be due to 
several reasons, which include: 
• The lead for our university department of vascular surgery was involved in the 
formulation of CG 168 
• These guidelines were publicised locally by writing to GP colleagues to inform 
them of the importance of the new guidelines. 
• Local, contemporaneous, promotion of the importance of leg ulcer referral from 
general practices to enhance recruitment into the Early Venous Reflux Ablation 
(EVRA) ulcer trial. 
• The academic department of vascular surgery has a pre-existing interest in venous 
disease and its treatment with widely published previous research, which may have 
increased referrals. 
 
Primary care data was obtained from the THIN database. This national network of GP 
practices provides all of their patient data in anonymous form for analysis. Practices that 
participate however, may be more likely to take part in research and perhaps be more 
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‘forward thinking’ and consequently aware of current research and clinical guidelines? 
Practices involved in contributing to the THIN database are not randomly selected 
throughout the UK and this feature may introduce a degree of selection bias in the patients 
that are included. There is also a small financial incentive for practices recording 
anonymous patient data into the THIN database and this might represent another source of 
bias. The UK, however has been quick to adopt electronic patient record data analysis and 
the results produced are of generally high quality, particularly those relating to chronic 
disease and prescribing 239. The results are however, dependent upon individual clinicians 
coding diseases, diagnoses and treatments correctly and their individual assessment of 
whether the episode is relevant to the patients’ care and thus worth coding. This is 
complicated somewhat by the ability to use several codes with similar meaning, this 
necessitates very careful interrogation of Read codes to identify all potential ways of 
coding the condition of interest as based on the International Classification of Diseases 
(ICD)-10 240. Indeed the ICD-10 includes over 14000 codes! Analysis of the incidence of 
CEAP scores in the primary care patients would have been interesting, but unfortunately, 
there is no extant method to ensure accurate coding for disease severity. This is 
disappointing and prevents an understanding of whether probability of referral to 
secondary care was dependent on severity of CEAP score.  
 
Some data deemed to be less important (e.g. ethnicity or BMI) is often poorly recorded and 
requires multiple imputation in constructing the Cox proportional hazard models to allow 
analysis between groups. Another confounding feature, as highlighted in Results sections 
3.4 and 3.5, is a result of interventions performed in secondary care being very poorly 
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recorded in the THIN database making comparison of interventions before and after 
CG168 rather difficult. The assumption was made that problems relating to coding in the 
pre-CG168 group were ostensibly, of similar prevalence in the post-CG168 group and 
consequently, although the numbers of recorded interventions were low, it was still 
possible to at least, broadly, compare trends in the data. Data for THIN is planned to be 
linked with HES data in the future which will improve the rate of recording of secondary 
care interventions but there will always remain a potential for error. 
 
4.2 THE ROLE OF NICE CG168 IN LOCAL SECONDARY CARE 
MANAGEMENT OF VENOUS DISEASE 
 
Careful planning was required by the HEFT vascular directorate before the introduction of 
NICE CG168 to allow for the predicted increase in VV and LU referrals. This involved 
consideration of the most efficient use of both outpatient clinic space and operating space 
for VV procedures in line with the predicted increase of 25% in activity 47. HEFT saw an 
increase of 65% in venous treatment activity after CG168 as described in Chapter 3.1.4 
and illustrated graphically in Figs.3.1.1 and 3.1.2. An increase in referrals and endovenous 
treatments was also noted nationally in the THIN database work (Chapter 3.4 and 
specifically for interventions in Tables 3.4.2 and 3.4.4). The data presented show that, in 
the author’s opinion, NICE CG 168 acted as a catalyst to secondary care activity and that 
this increased workload had to be absorbed into static resources of space and departmental 
personnel. 
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Prior to NICE CG168, in HEFT, as in most vascular departments, there was already an 
endovenous treatment programme underway. The recommendation for an ‘endovenous 
first’ treatment strategy was significant not only to improve patient outcomes and recovery 
(evidence reviewed in Chapter 2.1, page 19), but allows VV treatments to take place in 
‘procedure rooms’ rather than formal operating theatres. This is of great benefit to hospital 
theatre schedules as the projected increase in activity in venous treatments could be largely 
undertaken as day-cases in procedure room based procedures; this is far easier to resource 
in the cash-limited NHS environment than theatre space and in-patient hospital beds. The 
recommendation of ‘conventional surgery last’ again frees vascular operating room space 
for arterial cases and will have the benefit of improving waiting times for non-venous 
operations within hospitals vascular directorates.  
 
Improvement in management of VV disease in HEFT was supported by local clinical 
commissioning groups (CCGs) with financing of VV interventions in accordance with the 
new guidelines. CG168 provided a strong evidence-based framework for the referral, 
assessment and treatment of VV. Some commissioning groups elsewhere have considered 
VV to be procedures of ‘low-clinical value’ 241  and as such limited the commissioning of 
related services; this has resulted in significant variation in access to treatment around the 
country 50 and is not in accord with NICE recommendations. Sadly, further work by 
Carradice in 2018 has demonstrated that this regional variation is continuing and some 
CCGs are continuing to ration treatments48. While CCGs have local freedom of action, 
they have a complex relationship of accountability; the most significant is likely to be their 
accountability to NHS England 242. It is thus important that CCGs who are not compliant 
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with commissioning services in accordance with CG168 are highlighted to improve their 
compliance with national recommendations and thereby ensure equality of access to VV 
interventions across the NHS. It seems that lack of access to NICE recommended 
treatment may put CCGs at medico-legal risk, particularly if patients were able to 
demonstrate a deterioration from symptomatic C2 VV to skin damage and ulceration due 
to lack of appropriately timed referral and intervention or their intervention was denied by 
commissioners based on BMI in the presence of minimal evidence to exclude these 
patients from intervention (as reviewed in section 2.2). 
 
Review of previous UK publications of varicose vein activity suggests that the number of 
interventions was decreasing. Harris compares local treatments from 2000 compared to 
2002/352 and Lim reviewed treatment numbers using HES data between 2002-200649. Both 
describe significant reductions. HES data along with a freedom of information request for 
treatments commissioned by primary care trusts (the predecessors to CCGs) also revealed 
a national reduction in VV interventions year on year from 2008-201133. This tends to 
suggest that UK treatment numbers were reducing pre-CG168, but it cannot be ruled out 
that in the approach to the release of CG168 that treatment numbers had not started to 
increase from 2012-2013. The HEFT data presented does suggest that even if this was the 
case, CG168 has still significantly increased treatment numbers locally regardless of that 
possibility. 
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Whilst the NHS costing report does predict an increase in expenditure for the NHS 
associated with the implementation of CG168, the increase is modest - £1200 per 100 000 
patients though this is perhaps an under-estimate of potential financial burden. This 
calculation includes only direct costs and savings from assessment and treatment of 
patients and does not include added costs such as litigation. VV litigation is certainly the 
most common cause for medico-legal cases in vascular surgery 243, 244. Although 
endovenous ablation methods have lower complication rates and certainly less risk of 
inadvertent major arterial or venous injury than conventional surgery, it is possible that the 
financial burden of medico legal claims to the NHS will not improve as a result of an 
increasing tendency toward litigation and higher patient expectations from these minimally 
invasive techniques 245? 
 
LU referrals increased significantly in number in East Birmingham as described in Chapter 
3.2 and e.g., in Table 3.2.1, pages 52 and 57, respectively); in preparation for this a 
specialist leg ulcer clinic was created. As a result there was no clinically significant 
increase in waiting times for specialist vascular review, the average increase was only just 
over 1 week (Chapter 3.2.4 and Table 3.2.1, respectively, pages 55 and 57; discussed in 
Chapter 3.2.5, page 61).). In terms of cost implication this service was supported by a 
research team who were not directly funded to staff this clinic, the author suspects that 
elsewhere it may be difficult to deliver this service without impacting other services or 
departmental budgets. This considerable increase in referral of leg ulcer patients likely 
improved ulcer management for significant numbers in the HEFT catchment area with a 
statistically significant increase in endothermal ablation (Chapter 3.2.4 and Table 3.2.3, 
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pages 55 and 59, respectively). There are however, likely to be significant numbers of 
patients suffering ulceration in the community who are still being managed 
symptomatically with dressings, rather than having underlying ulcer aetiology diagnosed 
and treated as necessary by secondary care specialists. In East Birmingham, CG168 was 
followed by a significant decrease in the use of simple dressings, from 26% to 11.5%, 
p=0.0006, (Table 3.2.3) showing that within HEFT’s catchment area, CG 168 can be 
linked with improved community management of venous disease. 
 
Whilst the IMD data from local, East Birmingham secondary care for VV appears to show 
no disparity in access to treatment before and after NICE CG168 in terms of social 
deprivation using the Index of Multiple Deprivation Quintiles (IMD-Q) (Table 3.3.1). It 
appears there may be some limitation of access to LU patients in the most deprived social 
groups at a national level. The THIN database analysis, using Townsend Quintiles as 
indicators of social deprivation, suggested that smaller numbers of people with social 
deprivation received VV interventions with statistically significantly lower Cox Model 
hazard ratios for intervention than the ‘least-deprived’ reference group in Townsend 
Quintile 1 (Table 3.4.4). There is considerable need to confirm and if so, address this 
disparity.  
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4.3   THE ROLE OF NICE CG168 IN PRIMARY CARE MANAGEMENT AND 
REFERRAL OF VENOUS DISEASE 
 
CG168 guidelines recommendations appropriate for primary care are mainly based around 
referral (at CEAP C2) and the recognition that compression hosiery is no longer a suitable, 
general, treatment for VV.  The analysis using the THIN database demonstrated a marked 
improvement in referral numbers to secondary care along with a modest reduction in 
compression hosiery from 20% of patients to 18% after CG 168 when patients were 7% 
less likely to receive a prescription for pressure hosiery (hazard ratio 0.93, 95% CI 0.88-
0.89, p=0.008, section 3.4.4). Compression hosiery prescriptions still remained relatively 
high and prescriptions were commonly started just after initial consultation, within the first 
few days (Fig. 3.4.2) and certainly before they attended secondary care review, 
demonstrating that GP colleagues were still, perhaps, not fully aware of all of the 
recommendations.    
 
This increase in referrals will hopefully have improved the identification and treatment of a 
considerable number of VV patients since the introduction of CG168, as the chances of 
referral to a vascular specialist have seemingly increased, this, however, may be 
disproportionately biased towards those from less deprived areas with IMD-Q1/2 and 
Townsend Quintile 1 patients favoured? This work is based on GP coded referrals; it does 
not specify whether patients were referred for private practice or NHS vascular review.  If 
private practice is considered (most patients undergoing private VV intervention are likely 
to be from more affluent areas, therefore IMD – Q1/2), this may bias the dataset, indeed 
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examining the data from HEFT secondary care (solely NHS patients), as described above 
(section 3.3) did not show a bias towards any one IMD quintile.  
 
In contrast to improvements noted locally (Chapter 3.2) in LU care, the data obtained from 
the THIN database did not show any significantly improved compliance with CG 168 in 
the primary care management of these patients including referral to vascular specialists. 
Whilst there was an increase in absolute numbers of referrals to vascular care, statistically 
this was not significant (Table 3.5.5). This is unfortunate as the early referral after two 
weeks of ulceration is a key part of improving chronic venous insufficiency care in CG168. 
LU patients are often poorly served, for multiple reasons. Anecdotally, LU is less 
‘clinically exciting’ for surgeons, patients may be self-neglectful and from more socially 
deprived backgrounds and likely to present at more advanced disease states and be less 
compliant with treatment regimens. It is a shame that CG168 does not appear to have made 
an improvement here, where it has, perhaps, the highest potential to improve quality of life 
for patients and their families/carers? It is possible that CG168 does not place guidance for 
LU referral prominently enough within its structure. The multiplicity of other sources of 
leg ulcer guidance (RCN and SIGN) that are more likely to be read by district and practice 
nurses who are the ones most likely to see and manage LU patients in the community may 
add to the problem. GP colleagues often do not see LU patients who can be managed 
conservatively in the community for it may take many months before review by a doctor 
and eventual consideration of referral to a vascular specialist.  
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4.4    POTENTIAL FUTURE DIRECTIONS OF NICE VENOUS   GUIDELINES 
 
An overarching conclusion to emerge from the work programmes in this thesis is the 
importance of GP and patient/public awareness. It is difficult for GPs to remain abreast of 
all current NICE guidelines due to their sheer size and number and the heavy workload in 
primary care. It may be pertinent to consider publishing primary care summaries 
containing only the information relevant to general practice to enhance the ability of 
practitioners to consider current guidance. For example, could CG168 be simply 
summarised as: 
• Provide simple advice on varicose veins and lifestyle advice 
• Refer the following for specialist opinion: 
Ø Symptomatic varicose veins 
Ø Those with skin changes (eczema/pigmentation) or bleeding 
Ø Superficial thrombophlebitis 
Ø Those with skin break below the knee present for longer than 2 weeks 
• Compression hosiery is not a recommended treatment for varicose veins unless the 
patient is not suitable for intervention (e.g. during pregnancy). 
 
This simple summary can then reference guidelines where interested practitioners can find 
greater detail if necessary. Whilst this might not be possible with all NICE guidelines it 
would certainly help reduce the burden upon primary care, leaving the in depth knowledge 
to specialists who may have considerably fewer guidelines relevant to their practice. 
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It is also important to ensure patients are health aware and can seek help from their GPs. 
This is particularly important in the more socially deprived areas. NICE CG168 has a 
concurrent patient information resource, which is thorough and describes the basics of 
venous disease and treatments along with providing links to other patient resources. In the 
current financial climate advertising changes to treatment availabilities on 
television/internet is probably unattainable; however, local advertising in community 
centres/GP practices with clear posters is possible. This is particularly important with 
CG168. A large number of patients who were previously deemed to have a medical 
problem of low clinical significance (symptomatic varicose veins) are now eligible for 
treatment recommended by evidence -based guidance that, if followed, could appreciably 
improve their quality of life. It is also important for patients with leg ulceration to 
understand their entitlement to referral for specialist opinion, rather than waiting for weeks 
to months having their ulcer ‘treated’ with regular dressings.  
 
The conclusion from Chapters 3.1 to 3.5 must be that whilst things have improved locally 
for LU patients the national situation seems less agreeable and much needs to be done to 
improve matters. In terms of guidelines, CG168 makes strong recommendations to refer 
patients with leg ulcers after two weeks; however, there remains confusion with the SIGN 
and RCN guidelines recommending referral after twelve weeks. A unified set of guidelines 
could encourage the awareness of community health practitioner colleagues of the 
importance of timely aetiological diagnosis and treatment of LU. Both SIGN and RCN are 
in need of urgent review hopefully to embody the evidence-based recommendations of CG 
168.  
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One year data from the EVRA trial 246 demonstrates the improved healing times from a 
median of 82 to 56 days and increased ‘ulcer free’ time over the first 12 months of follow 
up with early (within 2 weeks of specialist review) endovenous intervention. There was 
also an improvement in the quality of life of patients and the findings were highly cost 
effective. This randomised controlled trial will surely significantly influence the review of 
CG168 and strengthen the recommendations for LU patients, building upon the ESCHAR 
trial data from almost 15 years ago! 
 
Perhaps further exploration of treatment hierarchy is required in the next revision of NICE 
guideline CG168; with increasing financial pressures it is difficult to accept a more 
expensive treatment strategy (endothermal) as a first line over UGFS (discussed in depth in 
Chapter 2.1) when in terms of patient reported outcomes, symptomatic improvement is 
similar? This is particularly pertinent given the recognition of patient reported outcomes 
becoming more widely recognised for their importance rather than anatomical 
closure/absence of treated superficial veins as a marker of treatment success. As with the 
acceptance of endothermal and UGFS treatments, new guidelines will need to address the 
results of still newer non-thermal, non-tumescent treatment modalities (cyanoacrylate glue 
and mechano-chemical ablation) 247.  Consideration of what recommendations are 
appropriate for these techniques is needed; it seems likely that the status of these 
treatments will be deferred whilst evidence for their use (or at least their non-inferiority) is 
accumulated and the equipment costs decrease. 
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There has been a considerable shift in approach to venous disease over the past few years. 
The importance of recognition of deep venous disease and the prevention of its sequelae 
(post-thrombotic syndrome and LU) along with novel endovenous treatment strategies for 
both acute and chronic deep venous disease are steadily acquiring an evidence base. The 
corresponding treatments are expensive and evidence in terms of randomised controlled 
trials and registry data is limited at present. Is it therefore likely that in the future there will 
evolve a separate clinical guideline for deep venous disease and associated interventions?  
 
CG168 only mentions excess weight and venous disease in terms of advising patients of 
weight loss as part of lifestyle measures and referring clinicians to NICE CG43 248 (the 
clinical guideline for obesity management). As described in Chapter 2.2, ‘phlebesity’ is 
increasing in prevalence. Current evidence suggests obesity as a potential contributing 
factor to venous disease and also demonstrates these patients have more severe symptoms 
and are more likely to have a higher CEAP clinical grade than their normal-weight 
counterparts. This perhaps makes obese patients more in need of treatment for venous 
disease, yet these patients are technically more difficult to treat as well as being at greater 
risk of complications post- procedure.  As the evidence grows in this area guidance will be 
required to aid clinicians’ decision-making and support decisions to intervene or manage 
conservatively as appropriate. 
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4.5  FUTURE DIRECTION OF RESEARCH ASSOCIATED WITH NICE 
GUIDELINES 
 
The presented thesis attempts to examine the impact of CG168 upon the management of 
superficial venous disease by studying primary care and secondary care responses. A 
national overview for England, of the effect of CG168 has been gleaned from the THIN 
database in terms of the primary care perspective, further research is required to examine 
whether CG168 has had any impact at a national level in secondary care. The absence of 
an accurate, nation wide database makes the latter task extremely difficult to perform. It is 
suspected that there would be considerable variation around the UK in the uptake and 
adherence to the guidelines. This variation will be a combination of local clinical 
commissioning groups disregarding the guidance and not commissioning enough 
endovenous procedures from secondary care providers and local secondary care variance 
in procedures and pathways. The expense of producing NICE guidelines means that 
ensuring their utilisation is imperative; otherwise with limited NHS budgets this money 
may be better spent elsewhere. Exploration of this area could be based upon a search of 
hospital episode statistics and perhaps providing an additional ‘clinician’ component to the 
current VV PROMs data collection that is already underway? This data would not only 
yield information on adherence to NICE guidelines but could also provide data on equality 
of access to interventions around the UK, perhaps improving the ‘postcode lottery’ leading 
to some variance in access to healthcare.  
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Increased data on nationwide management of venous disease would allow better cost 
modelling for predicting NHS budget requirements. It would also allow consideration of 
the role of independent sector treatment centres (ISTCs) for the assessment and treatment 
of superficial venous disease. ISTCs contracts require further investigation into their cost-
effectiveness as the present system of guaranteed payments may result in under-delivery of 
treatments and thus result in a financial loss to the NHS. There is also a reduction in 
‘profitable’ services for ‘low-risk’ patients with low levels of co-morbidity undergoing 
out-patient based venous interventions for NHS hospitals and a reduction in training 
opportunities by ISTCs taking straightforward cases away from teaching hospitals. 
 
There is also a need for further investigation into the effects of social deprivation upon leg 
ulcer patients. At present these patients lack optimal service and change is required to 
improve their predicament. It may be that community based leg ulcer clinics would 
encourage and empower these patients to present at an earlier stage to specialists, 
correspondingly appropriate management could be initiated in the community. This would 
require relatively little resources; the majority of patients require a 
history/examination/venous ultrasound (from a portable scanner) to identify any reversible 
causes and treatment with compression bandages could be initiated before referring on 
those with superficial venous reflux for consideration of intervention and those whose 
ankle-brachial pressure index suggests arterial insufficiency or whose underlying 
pathology was non-vascular in nature.  
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4.5.1   Suggestions For Future Studies 
• Study of adherence/non-adherence to NICE guidelines and reasons behind CCG 
non-adherence. This could be performed by freedom of information requests to 
individual CCGs with corroboration via questionnaires sent to Vascular Society of 
Great Britain and Ireland members to detect geographical variation and access to 
treatments as per CCG commissioning. 
Ø Hypothesis – CCGs are rationing  treatments due to financial constraints. 
 
• Investigation into nationwide numbers of varicose vein interventions post-CG168. 
This could be performed by analysis of HES data thus monitoring numbers of 
interventions performed to gauge changes in commissioning VV interventions 
against NICE guidance.  
Ø Hypothesis – VV interventions would have increased post-CG168 and be 
maintained at steady state. 
 
• Investigation into social deprivation and the incidence of VV and LU diagnoses. 
This may be achieved by further analysis of patient data from existing 
epidemiological databases (e.g. the Edinburgh or Bonn vein studies) provided it is 
possible to identify deprivation by, e.g., postcode; however the limitations of these 
methods of social deprivation assessment have been discussed earlier in this thesis. 
Additionally the Bonn and Edinburgh studies were not contemporaneous or 
sufficiently recent. The data could reflect frequency/availability of VV 
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interventions within different social groups to identify any prejudicial effects of 
social deprivation. 
Ø Hypothesis – VV and LU are associated with social deprivation. 
 
• Further study of possible linkage of social deprivation, age and sex on referral for 
VV and LU within the limitations of interrogation of the THIN or other primary 
care databases. 
Ø Hypothesis – young females from less socially deprived areas are more 
likely to present seeking VV interventions. Elderly females from less 
socially deprived areas are more likely to seek LU referral. 
 
• Considerable work on obesity and venous disease is required. 
Ø Does obesity affect success/longevity of endovenous interventions? 
Ø Does obesity increase complications after endovenous interventions? 
Ø Do obese patients have similar improvement or lesser/greater improvements 
in quality of life after superficial venous interventions? 
Answers to the above questions will help shape recommendations in future NICE clinical 
guidelines for venous disease. 
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Chapter 5 
CONCLUSION 
 
NICE CG168 has recommended substantial changes and improvements for the 
management of superficial venous disease in the UK. This thesis has demonstrated that 
after introduction of CG168 there has been a significant increase in referral of VVs to 
secondary care and that at least locally, there as been an increase in treatments for VVs. 
This has been particularly in those with symptomatic CEAP C2 VVs who previously were 
not treated with intervention. There has also been a marked shift towards endovenous first 
treatment strategy as recommended by CG168.  
 
The impact on leg ulcer patients sadly, has been less marked. There has been no real 
difference in the referral of people with leg ulcers from primary care as evinced by 
evidence from the THIN database. More promisingly, locally, in East Birmingham, there 
has been a considerable increase in the number of patients referred; however, these patients 
are not being referred any earlier than ‘before CG168’. There also appears to be a possible 
disadvantage to the socially deprived that requires further investigation.  
 
Overall, whilst there has been improvement, further work is required to ensure greater 
awareness amongst community practitioners of CG168, to enhance referral from primary 
care for specialist vascular assessment, to encourage understanding by commissioners to 
adequately fund services and to promote greater awareness in the general public to seek 
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advice for their lower limb venous disease. Future superficial venous guidelines will need 
to consider addressing these areas of need. 
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APPENDIX 3 – Read Codes To Identify THIN Database 
Patients 
Read Codes To Identify Varicose Vein Patients 
 
Read code Description 
2482.00 O/E - varicose veins 
G83..00 Varicose veins of the legs 
G830.00 Varicose veins of the leg with ulcer 
G831.00 Varicose veins of the leg with eczema 
G831.11 Varicose eczema 
G832.00 Varicose veins of the leg with ulcer and eczema 
G833.00 Varicose veins of the leg with rupture 
G834.00 Varicose veins of leg without mention of complications 
G834000 Varicose veins of leg with long saphenous vein distribution 
G834100 Varicose veins of leg with short saphenous vein distribution 
G835.00 Infected varicose ulcer 
G836.00 Varicose vein of leg with phlebitis 
G837.00 Venous ulcer of leg 
G83z.00 Varicose veins of the leg NOS 
G85..00 Other varicose veins 
G85y.00 Other specified varicose veins 
G85z.00 Other varicose veins NOS 
Gyu8600 [X]Varicose veins of other specified sites 
L41..11 Varicose veins - obstetric 
L410.00 Varicose veins of legs in pregnancy and the puerperium 
L410000 Varicose veins of legs in pregnancy/puerperium unspecified 
L410100 Varicose veins of legs in pregnancy/puerperium - delivered 
L410200 
Varicose veins of legs in pregnancy/puerperium -del+p/n 
comp 
L410300 Varicose veins of legs in pregnancy/puerperium + a/n comp 
L410400 Varicose veins of legs in pregnancy/puerperium + p/n comp 
L410500 Varicose veins of legs in pregnancy 
L410600 Varicose veins of legs in the puerperium 
L410z00 Varicose veins of legs in pregnancy and puerperium NOS 
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Read Codes To Identify Leg Ulcer Patients 
 
Read code Description 
2G48.00 O/E - ankle ulcer 
2G54.00 O/E - Right foot ulcer 
2G55.00 O/E - Left foot ulcer 
2G5H.00 O/E - Right diabetic foot - ulcerated 
2G5L.00 O/E - Left diabetic foot - ulcerated 
2G5V.00 O/E - right chronic diabetic foot ulcer 
2G5W.00 O/E - left chronic diabetic foot ulcer 
8CMT.00 Leg ulcer care pathway 
8CS3.00 Agreeing on leg ulcer treatment plan 
8CT1.00 Leg ulcer compression therapy finished 
8CV2.00 Leg ulcer compression therapy started 
9NM5.00 Attending leg ulcer clinic 
C108500 Insulin dependent diabetes mellitus with ulcer 
C108511 Type I diabetes mellitus with ulcer 
C108512 Type 1 diabetes mellitus with ulcer 
C109400 Non-insulin dependent diabetes mellitus with ulcer 
C109411 Type II diabetes mellitus with ulcer 
C109412 Type 2 diabetes mellitus with ulcer 
C10E500 Type 1 diabetes mellitus with ulcer 
C10E511 Type I diabetes mellitus with ulcer 
C10E512 Insulin dependent diabetes mellitus with ulcer 
C10F400 Type 2 diabetes mellitus with ulcer 
C10F411 Type II diabetes mellitus with ulcer 
G830.00 Varicose veins of the leg with ulcer 
G832.00 Varicose veins of the leg with ulcer and eczema 
G835.00 Infected varicose ulcer 
G837.00 Venous ulcer of leg 
M271.00 Non-pressure ulcer lower limb 
M271.11 Foot ulcer 
M271.12 Ischaemic leg ulcer 
M271.13 Leg ulcer NOS 
M271.14 Neurogenic leg ulcer 
M271.15 Trophic leg ulcer 
M271000 Ischaemic ulcer diabetic foot 
M271100 Neuropathic diabetic ulcer - foot 
M271200 Mixed diabetic ulcer - foot 
M271300 Arterial leg ulcer 
M271400 Mixed venous and arterial leg ulcer 
M271500 Venous ulcer of leg 
M271600 Traumatic leg ulcer 
M271700 Neuropathic foot ulcer 
M273.00 Non-healing leg ulcer 
M274.00 Recurrent leg ulcer 
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Read Codes To Identify Varicose Vein Intervention 
 
Read code Description 
7A66100 Subfascial ligation of perforating vein of leg 
7A66111 Cockett subfascial ligation of perforating varicose vein 
7A66112 Subfascial ligation of varicose veins 
7A66y00 Other specified other operation for venous insufficiency 
7A66z00 Other operation for venous insufficiency NOS 
7A67.00 Ligation of varicose vein of leg 
7A67000 Ligation of long saphenous vein 
7A67011 Trendelenburg ligation of long saphenous vein 
7A67100 Ligation of short saphenous vein 
7A67200 Ligation of recurrent varicose vein of leg 
7A67300 Ligation of perforating varicose vein of leg 
7A67311 Linton ligation of perforating varicose vein of leg 
7A67400 High ligation of long saphenous vein 
7A67411 High tie ligation 
7A67y00 Other specified ligation of varicose vein of leg 
7A67z00 Ligation of varicose vein of leg NOS 
7A68.00 Injection into varicose vein of leg 
7A68000 Injection of sclerosing substance into varicose vein of leg 
7A68100 Microsclerotherapy to spider veins of leg 
7A68200 Ultrasound guided foam sclerotherapy for varicose vein leg 
7A68300 Transilluminated powered phlebectomy of varicose vein of leg 
7A68400 Injection of sclerosing substance into varicose vein leg NEC 
7A68y00 Other specified injection into varicose vein of leg 
7A68z00 Injection into varicose vein of leg NOS 
7A69.00 Other operations on varicose vein of leg 
7A69000 Stripping of long saphenous vein 
7A69100 Stripping of short saphenous vein 
7A69200 Stripping of varicose vein of leg NEC 
7A69211 Mayo stripping of varicose vein 
7A69300 Avulsion of varicose vein of leg 
7A69311 Babcock subcutaneous enucleation of varicose veins 
7A69400 Local excision of varicose vein of leg 
7A69500 Incision of varicose vein of leg 
7A69600 Endovascular radiofrequency ablation of varicose vein of leg 
7A69700 Endovascular laser ablation of varicose vein of leg 
7A69y00 Other specified other operation on varicose vein of leg 
7A69z00 Other operation on varicose vein of leg NOS 
7A6L.00 Combined operations on varicose vein of leg 
7A6L000 Combined operations on primary long saphenous vein 
7A6L100 Combined operations on primary short saphenous vein 
7A6L200 Combined operations on primary long and short saphenous vein 
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7A6L300 Combined operations on recurrent long saphenous vein 
7A6L400 Combined operations on recurrent short saphenous vein 
7A6L500 Combined operations recurrent long and short saphenous vein 
7A6Ly00 Other specified combined operations on varicose vein of leg 
7A6Lz00 Combined operations on varicose vein of leg NOS 
7A6M.00 Transluminal operations on varicose vein of leg 
7A6M000 Percutaneous transluminal laser ablation long saphenous vein 
7A6M100 Radiofrequency ablation of varicose vein of leg 
7A6M200 Percutaneous transluminal laser ablation of vein NEC 
7A6M300 Perc transluminal laser ablation of varicose vein of leg NEC 
7A6My00 Other specified transluminal operations on varicose vein leg 
7A6Mz00 Transluminal operations on varicose vein of leg NOS 
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APPENDIX 4 – Papers Arising 
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